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AKR         Aldo-keto reductase 
AR           Human aldose reductase 
AKR1B10     Human aldose reductase-like protein 
BAEC        Bovine aorta endothelial cells 
BDMC    Bisdemethoxycurcumin 
CBR         Carbonyl reductase 
CAPE     Caffeic acid phenethylester;  
CBR1     Carbonyl reductase 1 
CDDP    Cisplatin 
DCXR        Dicarbonyl/L-xylulose reductase 
DHRS4       Dehydrogenase/reductase SDR family member 4  
DMAP    4-dimethylaminopyridine 
DMEM    Dulbecco’s modified Eagle medium 
DMSO    Dimethyl sulfoxide 
EDC     1-ethyl-3-(3-dimethylaminopropyl)carbodiimide 
EGFR     Epithelial growthfactor receptor 
Hydroxy-PP   3-(1-tert-Butyl-4-amino-1H-pyrazolo[3,4-d]pyrimi-din-3-yl)phenol 
NSCLC   Non-small-cell lung carcinoma 
SDR         Short-chain dehydrogenase/reductase 
S-Tetralol     (S)-(+)-1,2,3,4-Tetrahydro-1-naphthol  
































































第 2節 これまでの CBR1阻害剤 
これまでに知られている CBR1阻害剤はそれほど多くなく、またその阻害
効果も必ずしも満足のいくものではない。その中で最も強力な阻害剤として、






























       Ethacrynic acid
(45% inhibition at 0.1 μ M )8
     Triclosan
(IC50
=0.4 μ M )10
    Hydroxy-PP
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=0.78 μ M )9
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=0.21 μ M )10
     Curcumin
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=0.22 μ M )11
       Luteolin
(IC50
=0.095 μ M )12  
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Table 1 Inhibitory effects of the chromene derivatives with or without the 4-methoxyphenyl moiety on 










aThe values are taken from refs. 13 and 14. 
 bLess than 33% inhibition at 10 μM. 
IC50 (μM) 
Compound R1 R2 CBR1 AKR1B10 AKR1B1 
1 7-OH 4-Methoxyphenyl 0.25±0.021 0.006a 0.011a 
2 5-OH 4-Methoxyphenyl 0.53±0.062 0.29a >10b 
3 6-OH 4-Methoxyphenyl >10b >10b >10b 
4 8-OH 4-Methoxyphenyl >10b >10b >10b 
5 H 4-Methoxyphenyl >10b >10b >10b 
6 7-OH H 3.0±0.27 0.099±0.010 0.53±0.078 
7 5-OH H 5.3±1.1 1.5±0.045 >10b 
8 6-OH H >10b >10b >10b 
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    THF,40oC,24h
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13a:R=H,n=0           (82%)
13b:R=2-OH,n=0     (48%)
13c:R=3-OH,n=0     (40%)
13d:R=4-OH,n=0     (46%)
13e:R=2-F,n=0        (82%)
13f:R=3-F,n=0         (51%)    
13g:R=4-F,n=0        (65%)  
13h:R=2-Cl,n=0       (67%)
13i:R=3-Cl,n=0        (65%) 
13j:R=4-Cl,n=0        (91%)
13k:R=H,n=1           (55%)
13l:R=2-OH,n=1      (62%)
13m:R=3-OH,n=1    (46%)
13n:R=4-OH,n=1     (24%)
13o:R=2-Cl,n=1       (85%)
13p:R=3-Cl,n=1       (90%)
13q:R=4=Cl,n=1      (93%)
10%HCl (5drops)








14a:R=H,n=0           (81%)
14b:R=2-OH,n=0     (81%)
14c:R=3-OH,n=0     (83%)
14d:R=4-OH,n=0     (52%)
14e:R=2-F,n=0        (98%)
14f:R=3-F,n=0         (85%)    
14g:R=4-F,n=0        (89%)  
14h:R=2-Cl,n=0       (95%)
14i:R=3-Cl,n=0        (47%) 
14j:R=4-Cl,n=0        (54%)
14k:R=H,n=1           (99%)
14l:R=2-OH,n=1      (50%)
14m:R=3-OH,n=1    (81%)
14n:R=4-OH,n=1     (99%)
14o:R=2-Cl,n=1       (71%)
14p:R=3-Cl,n=1       (90%)
14q:R=4=Cl,n=1      (73%)  
 
その結果、KO81のピリジン環をベンゼン環に変えた 13aの阻害活性が僅か






























    
R3 Entry IC50(μM) Entry IC50(μM) 
Phenyl 13a 0.21±0.012 14a 1.9±0.16 
2-Hydroxyphenyl 13b 0.33±0.025 14b 0.47±0.028 
3-Hydroxyphenyl 13c 0.15±0.011 14c 0.37±0.030 
4-Hydroxyphenyl 13d 0.88±0.045 14d 1.3±0.066 
2-Fluorophenyl 13e 0.31±0.037 14e 1.8±0.42 
3-Fluorophenyl 13f 0.37±0.045 14f 2.5±0.15 
4-Fluorophenyl 13g 0.44±0.086 14g 2.5±0.11 
2-Chlorophenyl 13h 0.034±0.0035 14h 0.26±0.037 
3-Chlorophenyl 13i 0.12±0.015 14i 1.5±0.082 
4-Chlorophenyl 13j 0.22±0.015 14j 0.45±0.082 
Benzyl 13k 0.33±0.03 14k 0.92±0.0091 
2-Hydroxybenzyl 13l 0.35±0.026 14l 1.3±0.18 
3-Hydroxybenzyl 13m 0.11±0.0011 14m 1.1±0.051 
4-Hydroxybenzyl 13n 0.17±0.022 14n 0.82±0.013 
2-Chlorobenzyl 13o 0.10±0.013 14o 0.41±0.019 
3-Chlorobenzyl 13p 0.090±0.00064 14p 1.1±0.072 




















ロメン酸素と Ser139および８位フェノール性水酸基と Ser139, lle140との間に水
素結合による相互作用があることを確認した。（Figure 3） 
 
Fig. 3 13h-docked CBR1 model. NADP+ (yellow) and residues (grey) within 4.0 Å from 13h (pink) are depicted 
with possible H-bonds (dotted line) and their corresponding distances are shown in Å. Only side-chains are 



















Table 3 Inhibitory effects of 13h, 13p and 13o on human enzymes in the SDR and AKR superfamilies 
 13h 13p 13o Luteolin 
Enzyme IC50a SRb IC50a SRb IC50a SRb IC50a SRb 
CBR1 0.034 - 0.090 - 0.1 - 0.095c - 
CBR3 1.5±0.16 44 >10 >110 2.5±0.026 25 0.53±0.052 6 
DGXR >10 >290 >10 >110 >10 >100 6.6±0.39 69 
DHRS4 >10 >290 >10 >110 >10 >100 5.3±0.38 56 
AKR1B10 >10 >290 3.7±0.010 34 4.8±0.31 48 0.73±0.058 8 
AKR1B1 >10 >290 >10 >110 >10 >100 0.18±0.010 2 
AKR1C1 >10 >290 >10 >110 >10 >100 1.9±0.11 20 
AKR1C2 >10 >290 >10 >110 >10 >100 6.7±0.31 71 
AKR1C4 >10 >290 >10 >110 >10 >100 1.7±0.10 18 
a IC50 (μM) was determined as described in section 3.2.2. >10: less than 36% inhibition at 10 μM. b SR: selectivity 
ratio of the IC50 value for other 

































































選択性が低く改善の余地が残されていた。（Table  4） 














structuresa IC50b(nM) Ratio 
R1 R2 R3 R4 R5 AKR1B10 AR AR/1B10 
1 H H H OCH3 H 6.0±0.3 11±1 1.8 
2 H OCH3 H OCH3 H 15±3 21±2 1.4 
3 H OCH3 H H OCH3 22±1 36±1 1.6 
4 CH3 H OCH3 OCH3 H 36±3 34±5 0.9 
a R1–R5 are substituents of PHPC, (Z)-2-(phenylimino)-7-hydroxy-N-(pyridin-2- 
yl)-2H-chromene-3-carboxamide 



























AR    IC50 
= 4900±400 nM
selectivity 790  





































































1B10 IC50=7.5nM, selectivity 1B10:AR=2:1
1B10 IC50=4.2nM, selectivity 1B10:AR=49:1  













Table 5 Inhibition of AKR1B10 and AKR1B1 by Coumarin Derivatives 
 




19a 3 3’-OH H OH H 8.3 ± 1.4 180 ± 1 22 
19b 3 2’-OH H OH H 6.4 ± 0.4 220 ± 19 34 
19c 3 4’-OH H OH H 4.2 ± 0.2 204 ± 4 49 
19d 3 3’-F H OH H 6.0 ± 1.4 340 ± 42 57 
19e 3 4’-F H OH H 3.5 ± 0.1 277 ± 17 79 
19f 3 3’,5’-diF H OH H 7.8 ± 0.3 320 ±49 41 
19g 3 4’-Me H OH H 7.0 ± 0.6 200 ± 14 29 
19h 3 4’-OMe H OH H 11 ± 0.9 390 ± 40 35 
19i 4 4’-OH H OH H 11 ± 0.2 314 ± 27 27 
19j 3 4’-OH H H H 2,700 ± 400 >10,000 b >4 
19k 3 4’-OH OH H H 1,500 ± 70 9,500 ± 750 6 
19l 2 4’-OH H OH H 20 ± 1.0 98 ± 9.1 5 

















16b: n=3, R1=2-OMOM 16g: n=3, R1=4-Me
16c: n=3, R1=4-OMOM 16h: n=3, R1=4-OMe


















17a': n=3, R1=3-OH       17g: n=3, R1=4-Me
17b: n=3, R1=2-OMOM 17h: n=3, R1=4-OMe
17c: n=3, R1=4-OMOM 17i: n=4, R1=4-OMOM
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Table 6 Inhibitory Effects of 19c and 19e on AKRs and CBR1 
Enzyme substratea 
19c 19e 
IC50 (nM) Ratio b IC50 (nM) Ratio b 
AKR1B10 20 μM P3A 4.1 ±0.3 1 3.4 ±0.1 1 
AKR1A1 2.0 mM P3A* 1,500 ± 10 370 1700 ± 910 500 
AKR1C1 7 μM S-Tetralol 950 ± 25 230 12000 ± 600 3500 
AKR1C2 260 μM S-Tetralol 970 ± 57 240 610 ± 2 180 
AKR1C3 1.4 mM S-Tetralol 1600 ± 50 390 470 ± 19 140 
AKR1C4 110 μM S-Tetralol 820 ± 31 200 350± 19 100 
CBR1 50 μM Isatin 4,200 ± 400 1,000 1,100 ± 140 310 
aSubstrate concentrations of AKRs correspond to the approximate Km 
values, which were reported and determined in this study (*). 



































proliferative assayにおいて有意に浸潤性、増殖性を抑制した。（Figure 7） 
 
Fig.7 Inhibition of invasive and proliferative potential of A549 cells by 19c and 19e. (A) Wound-healing assay. 
The cells were scratched and then treated for 24 h with vehicle dimethyl sulfoxide (DMSO), 20 μM 19c, or 20 
μM 19e. As representative photographs at 0 h and 24 h culture are shown, the cells migrated into the scratch 
wounds (two dotted lines). The migration distance of the inhibitor-treated cells is expressed as the percentage 
to that of the DMSO-treated control cells in the bar graph. Significant difference from the control cells, *p < 
0.05 (n = 3). (B) Proliferative assay. A549 cells (left) and A549/1B10 cells (right) were cultured in the absence 
or presence of the indicated concentrations of 19c and 19e, and the viable cell numbers were estimated at 96 h. 
Significant differences (p < 0.05) from the inhibitor free A549 cells and A549/1B10 cells are shown with * and #, 

















Fig.8 Overcoming CDDP resistance of A549 cells by treatments with 19c and 19e. (A) Effects of 19c and 19e on 
CDDP sensitivity of CDDP-R-A549 cells. The CDDP-R-A549 cells and parental A549 cells were pretreated for 
2 h without or with the indicated concentrations of 19c or 19e, and then treated for 24 h with 40 μM CDDP. 
The viability values are expressed as percentages to that of the parental cells treated without inhibitor. (B) 
Growth curves of A549 and CDDP-R-A549 cells in medium containing 0.5 μM CDDP (n = 3). (C) Effects of 19c 
and 19e on the growth of CDDP-R-A549 cells in the presence of 0.5 μM CDDP. The cells were cultured for 96 h 
in the absence or presence of 19c or 19e. The viable cell numbers are expressed as percentages to that of the 
parental A549 cells treated without inhibitor. Significant difference from CDDP-R-A549 cells treated without 










Fig.9 Inhibition of A549 cells metastasis into mouse lung by 19c and 19e. Cultured A549−Luc2 cells were 
treated with 20 μM 19c or 19e or vehicle DMSO (as a control) for 48 h and then injected into the tail vein of 
BALB/c nude mice (n = 5). After 4 days, luciferase luminescence in the lungs was evaluated. Significant 









































































































































































































































を行ったところ、化合物 20, 21, 24, 28, 36の５種類の化合物が優れていることが
判明し、特に化合物 20と 36が高いバインディング能を有することがわかった。
化合物 20と 36は構造的に異なっており、それぞれが Atg4Bの活性部位にどの










Fig. 10. Docked models of compounds 20 and 36 in Atg4B-LC3 complex. (A) Overall-structure of complex of 
Atg4B (magenta)-LC3 (right blue) (PDB:2Z0E). Dashed circle: catalytic domain of Atg4B. (B) Chemical 
structures of 20 and 36. (C, D) Close-up view of docking of 20 (C) and 36 (D) in the catalytic domain. The 
residues (magenta) of Atg4B within 4.0 Å from the compound (20 or 36, green) are depicted with possible 
hydrogen bond and salt-bridge interactions, which are shown in dotted lines with distances (Å). 
 
次に、化合物 20と 36の Atg4B阻害活性評価を検討した。その結果、両化
合物共に Atg4Bを効果的に阻害することが判明した。（IC50 of 1: 10 µM, 17 : 12 
µM）さらに両化合物を用いたシスプラチン抵抗性ヒト肺癌細胞 A549 に対する




























































Fig. 11. Overcoming CDDP resistance of A549 cells by treatments with compounds 20 and 36. (A) Effects of 20 
and 36 on CDDP sensitivity of A549/CDDP cells. The A549/CDDP cells and parental A549 cells were 
pretreated for 2 h without or with the indicated concentrations of 20 or 36, and then treated for 24 h with 50 
µM CDDP. The viability values are expressed as percentages to that of the parental cells treated without 
inhibitor. ** p < 0.01, * p < 0.05 versus A549/CDDP cells treated with CDDP alone. (B) CDDP-induced LC3-II 
production in A549/CDDP cells. The cells were treated with 50 μM CDDP. LC3-II in the cell extracts were 







































































The chromenes (13a–13q), 15, and the coumarins (14a–14q) were synthesized as 
shown in Scheme 1.  
General.  
A Yanaco micro melting apparatus was used to test melting points and were 
uncorrected. Flash chromatography was made by using Kanto Kagaku silica gel 60N. 
NMR spectra were tested on JEOL GX 400 and JEOL JNX-ECX500 spectrometers. 
Chemical shifts (δ) are given in ppm downfield from TMS and referenced to CHCl3 
(7.26 ppm) or DMSO (2.50 ppm) for 1H-NMR spectra and the centre line of CDCl3 
(77.0 ppm) for 13C-NMR spectra as an internal standard. Peak multiplicities are decided 
by the following abbreviations: s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; 
br, broad and coupling constants in (J) Hz. High-resolution mass spectral data were 
tested by a JEOL MStation JMS-700. All commercial reagents were used as received 
unless otherwise noted. The amides 12c, 12i, 12j, 12k, 12n, 12o, 12p, and 12q are 
bought from UORSY Building Blocks, Ukraine. 
General procedure for the preparation of 12.  
To a stirred solution of cyanoacetic acid (1 mmol) in CH2Cl2 (5 mL) were added EDC 
(2 mmol), DMAP (0.2 mmol), and the corresponding amine (1 mmol), and the resulting 
mixture was stirred overnight at 25ºC. The volatiles were removed under reduced 
pressure, and the residue was purified through chromatographed on silica gel (15 g, 
hexane : acetone = 5 : 1) to give the pure amide. The amides 12a, 12d, 12e, 12f, 12g, 
and 12h are known compounds, and the 1H-NMR spectra of our synthetic materials 













2-Cyano-N-(2-methoxymethoxybenzyl)acetamide. Yield: 45%; mp: 86–88 °C; 1H-NMR (500 
MHz, CDCl3) δ 3.33 (2H, s), 3.48 (3H, s), 4.47 (2H, d, J = 6.5 Hz), 5.24 (2H, s), 6.82 (1H, br), 
6.97 (1H, td, J = 6.5, 1.0 Hz), 7.13 (1H, dd, J = 6.5, 1.0 Hz), 7.25 (1H, d, J = 6.5 Hz), 7.26 (1H, 
td, J = 6.5, 1.0 Hz); 13C-NMR (125 MHz, CDCl3) δ 25.9, 40.6, 56.5, 94.8, 114.3, 122.1, 125.7, 
126.5, 129.7, 130.2, 155.6, 160.5; IR (KBr): 3291, 1653, 1559, 1155 cm−1; MS (EI): m/z 234 









2-Cyano-N-(3-methoxymethoxybenzyl)acetamide. Yield: 51%; mp: 83–85 °C; 1H-NMR (500 
MHz, CDCl3) δ 3.41 (2H, s),3.48 (3H, s), 4.45 (2H, d, J = 5.5 Hz), 5.17 (2H, s), 6.35 (1H, 
br),6.93 (1H, d, J = 6.5 Hz), 6.96 (1H, s-like), 7.00 (1H, dd, J =6.5, 2.5 Hz), 7.28 (1H, t, J = 6.5 
Hz); 13C-NMR (125 MHz, DMSO-d6) δ 25.5, 43.7, 55.8, 94.1, 114.8, 115.1, 115.4, 120.8, 129.6, 
138.6, 157.2, 161.9; IR (KBr): 3288, 1646, 1555, 1155, 1030 cm−1;  MS  (EI): m/z 234 (M+); 
HRMS: calcd for C12H14N2O3 234.2512, found: 234.0999. 
 
Deprotection of the MOM group  
10% HCl (5 drops) was added to a stirred solution of the acetoamides made above (1 
mmol) in THF (5 mL), and then the resulting mixture was kept to 40 °C for 24 h. After 
cooling, the reaction was quenched by H2O (5 mL) and the aqueous mixture  was  
extracted with EtOAc (5 mL × 3). The organic extracts were collected, dried by Na2SO4, 
and evaporated under reduced pressure. The residue was chromatographed on silica gel 










2-Cyano-N-(2-hydroxybenzyl)acetamide (12l). Yield: 91%; mp: 108–110 °C; 1H-NMR (500 
MHz, CDCl3) δ 3.43 (2H, s), 4.43 (2H, d, J = 6.5 Hz), 6.88 (1H, td, J = 6.5, 1.0 Hz), 6.93 (1H, 
dd, J = 6.5, 1.0 Hz), 6.98 (1H, br), 7.14 (1H, dd, J = 6.5, 1.0 Hz), 7.23 (1H, td, J = 6.5, 1.0 Hz), 
7.88 (1H, br); 13C-NMR (125 MHz, CDCl3) δ 25.6, 40.8, 114.3, 117.3, 120.4, 123.0, 130.2, 
130.8, 155.1, 163.2; IR (KBr): 3291, 1674, 1458 cm−1; MS (EI): m/z 190 (M+); HRMS: calcd 









2-Cyano-N-(3-hydroxybenzyl)acetamide (12m). Yield: 74%; mp: 85–87 °C; 1H-NMR (500 
MHz, CDCl3) δ 3.41 (2H, s), 4.43 (2H, d, J = 6.0 Hz), 6.40 (1H, br), 6.77 (1H, s), 6.78 (1H, dd, 
J = 7.5, 1.0 Hz), 6.83 (1H, d, J = 7.5 Hz), 7.22 (1H, t, J = 7.5 Hz); 13C-NMR (125 MHz, CDCl3) 
δ 25.8, 43.2, 114.5, 114.8, 116.8, 118.5, 129.9, 140.4, 158.0, 162.6; IR (KBr): 3209, 1653, 1558 
cm−1; MS (EI): m/z 190 (M+); HRMS: calcd for C10H10N2O2 190.0742, found 190.0741. 
 
General procedure for the preparation of 13. 
  11 (1 mmol) and piperidine (3 drops) were added to a stirred solution of cyanoamide 
12 (1 mmol) in ethanol (5 mL), and the resulting mixture was stirred for overnight at 
25OC. The solid product was filtered, washed with ethanol, and dried to obtained the 













8-Hydroxy-2-imino-2H-chromene-3-carboxylic acid phenylamide (13a). Yield: 82%; mp: 
235–237 °C; 1H-NMR (500 MHz, DMSO-d6) δ 7.07 (1H, d, J = 3.0 Hz), 7.08 (1H, d, J = 4.0 
Hz), 7.11 (1H, t, J = 7.5 Hz), 7.23 (1H, dd, J = 4.0, 3.0 Hz), 7.37 (2H, t, J = 7.5 Hz), 7.67 (2H, 
dd, J = 7.5, 1.0 Hz), 8.50 (1H, d, J = 1.5 Hz), 9.09 (1H, s), 10.23 (1H, br); 13C-NMR (125 MHz, 
DMSO-d6) δ 119.9, 120.1, 120.2, 120.4, 120.5, 124.5, 124.6, 129.6, 138.8, 142.5, 142.6, 144.5, 
156.5, 160.3; IR (KBr): 3298, 1674, 1598, 1473 cm−1; MS (EI): m/z 280 (M+); HRMS: calcd for 











8-Hydroxy-2-imino-2H-chromene-3-carboxylic acid (2- hydroxyphenyl)amide (13b). Yield: 
48%; mp: 253–255 °C; 1H-NMR (500 MHz, DMSO-d6) δ 6.80 (1H, td, J = 6.0, 2.0 Hz), 6.88–
6.92 (1H, 1H, and 1H, each d), 7.06 (1H, d, J = 2.5 Hz), 7.07 (1H, d, J = 4.5 Hz), 7.21 (1H, dd, J 
= 4.5, 2.5 Hz), 8.37 (1H, d, J = 8.0 Hz), 8.48 (1H, s), 8.98 (1H, s), 9.96 (1H, br), 10.20 (1H, br); 
13C-NMR (125 MHz, DMSO-d6) δ 115.23, 119.5, 119.97, 120.05, 120.5, 121.0, 124.5, 124.6, 
127.5, 142.0, 142.4, 142.5, 144.4, 147.7, 155.8, 160.1; IR (KBr): 3313, 1668, 1558, 1471 cm−1; 











8-Hydroxy-2-imino-2H-chromene-3-carboxylic acid (3-hydroxyphenyl)amide (13c). Yield: 
40%; mp: 202–204 °C; 1H-NMR (500 MHz, DMSO-d6) δ 6.52 (1H, dd, J = 7.0, 2.0 Hz), 6.97 
33 
 
(1H, dd, J = 7.0, 1.0 Hz), 7.08 (1H, d, J = 2.5 Hz), 7.09 (1H, d, J = 4.5 Hz), 7.14 (1H, t, J = 7.0 
Hz), 7.22 (1H, dd, J = 4.5, 2.5 Hz), 7.28 (1H, t, J = 2.0 Hz), 8.48 (1H, s), 9.08 (1H, s), 9.50 (1H, 
br), 10.20 (1H, br); 13C-NMR (125 MHz, DMSO-d6) δ 107.1, 110.8, 111.7, 119.9, 120.2, 120.5, 
120.6, 124.6, 130.3, 139.8, 142.5, 144.5, 156.5, 158.4, 160.1; IR (KBr): 3303, 1676, 1577, 1473 











8-Hydroxy-2-imino-2H-chromene-3-carboxylic acid  (4-hydroxyphenyl)amide(13d). 
Yield: 46%; mp: 231–233 °C; 1H-NMR (500 MHz, DMSO-d6) δ 6.76 (2H, d, J = 7.8 Hz), 7.07 
(1H, d, J = 3.0 Hz), 7.08 (1H, d, J = 3.5 Hz), 7.21 (1H, dd, J = 3.5, 3.0 Hz), 7.47 (2H, d, J = 7.8 
Hz), 8.46 (1H, s), 9.03 (1H, s), 9.34 (1H, br), 12.58 (1H, br); 13C-NMR (125 MHz, DMSO-d6) δ 
116.0, 119.96, 120.03, 120.5, 120.7, 121.7, 124.6, 130.5, 142.1, 142.4, 144.5, 154.5, 156.5, 












8-Hydroxy-2-imino-2H-chromene-3-carboxylic acid (2-fluorophenyl)amide (13e). Yield: 
82%; mp: 247–249 °C; 1H-NMR (500 MHz, DMSO-d6) δ 7.10 (1H, d, J = 8.0 Hz), 7.11 (1H, d, 
J = 10.0 Hz), 7.13–7.18 (1H, m), 7.23 (1H, d, J = 8.0 Hz), 7.26 (1H, dd, J = 8.0, 1.5 Hz), 7.33 
(1H, dd, J = 10. 0, 8.0 Hz), 8.48 (1H, td, J = 8.0, 1.5 Hz), 8.55 (1H, d, J = 1.5 Hz), 9.14 (1H, br); 
13C-NMR (125 MHz, DMSO-d6) δ 115.6 (d, J = 23.1 Hz), 119.8, 120.2 (d, J = 23.1 Hz), 120.7, 
121.9, 124.6, 125.0 (d, J = 8.5 Hz), 125.2 (d, J = 3.6 Hz), 127.0 (d, J = 8.5 Hz), 142.5, 143.1, 
144.5, 153.0 (d, J = 241.8 Hz), 156.3, 160.6; IR (KBr): 3310, 1607, 1569, 1473 cm−1; MS (EI): 













8-Hydroxy-2-imino-2H-chromene-3-carboxylic acid (3-fluorophenyl)amide (13f). Yield: 
51%; mp: 225–227 °C; 1H-NMR (500 MHz, DMSO-d6) δ 6.96 (1H, td, J = 7.0, 1.5 Hz), 7.06 
(1H, d, J = 2.5 Hz), 7.08 (1H, d, J = 4.5 Hz), 7.22 (1H, dd, J = 4.5, 2.5 Hz), 7.28 (1H, d, J = 9.0 
Hz), 7.39 (1H, q, J = 7.0 Hz), 7.74 (1H, d, J = 9.0 Hz), 8.50 (1H, s), 9.10 (1H, br), 10.22 (1H, 
br); 13C-NMR (125 MHz, DMSO-d6) δ 107.0 (d, J = 23.1 Hz), 110.0 (d, J = 23.1 Hz), 116.0, 
119.8, 120.1, 120.3, 120.6, 124.6 (d, J = 1.3 Hz), 131.1 (d, J = 10.3 Hz), 140.4 (d, J = 10.3 Hz), 
142.5, 142.9, 144.5, 156.4, 160.7, 162.8 (d, J = 239.4 Hz); IR (KBr): 3305, 1609, 1579, 1473 











8-Hydroxy-2-imino-2H-chromene-3-carboxylic acid (4-fluorophenyl)amide (13g). Yield: 
65%; mp: 240–242 °C; 1H-NMR (500 MHz, DMSO-d6) δ 7.09–7.10 (1H and 1H, each d), 7.22–
7.24 (2H and 1H, each dd), 7.71 (1H, dd, J = 5.0, 4.5 Hz), 8.50 (1H, s), 9.09 (1H, br); 13C-NMR 
(125 MHz,DMSO-d6) δ 116.1 (d, J = 23.1 Hz), 119.8, 120.2, 120.3, 120.5, 121.9 (d, J = 7.4 Hz), 
124.6 (d, J = 3.6 Hz), 135.2, 142.4, 142.6, 144.5, 156.4, 158.9 (d, J = 239.0 Hz), 160.3; IR 
(KBr): 3298, 1674, 1511, 1218 cm−1; MS (EI): m/z 298 (M+); HRMS: calcd for  C16H11FN2O3 













8-Hydroxy-2-imino-2H-chromene-3-carboxylic acid (2-chlorophenyl)amide (13h). Yield: 
67%; mp: 282–283 °C; 1H-NMR (500 MHz, DMSO-d6) δ 7.08–7.13 (1H, 1H, and 1H, each 
d), 7.16 (1H, td, J = 6.5, 1.5 Hz), 7.24 (1H, dd, J = 5.0, 2.0 Hz), 7.39 (1H, td, J = 7.0, 1.0 Hz), 
7.54 (1H, dd, J = 6.5, 1.5 Hz), 8.52 (1H, dd, J = 7.0, 1.0 Hz), 8.55 (1H, s), 9.13 (1H, s); 
13C-NMR (125 MHz, DMSO-d6) δ 119.8, 120.2, 120.4, 120.7, 122.6, 123.6, 124.6, 125.5, 
128.2, 129.9, 136.0, 142.5, 143.3, 144.5, 156.0, 160.8; IR (KBr): 3305, 1684, 1471, 












8-Hydroxy-2-imino-2H-chromene-3-carboxylic acid (3-chlorophenyl)amide (13i). Yield: 
65%; mp: 252–254 °C; 1H-NMR (500 MHz, DMSO-d6) δ 7.07–7.13 (1H and 1H, each d), 
7.18 (1H, d, J = 8.0 Hz), 7.23 (1H, d, J = 8.0 Hz), 7.39 (1H, t, J = 8.0 Hz), 7.44 (1H, d, J = 8.0 
Hz), 7.95 (1H, s), 8.50 (1H, s), 9.12 (1H, s); 13C-NMR (125 MHz, DMSO-d6) δ 118.6, 119.6, 
119.8, 120.1, 120.3, 120.6, 124.2, 124.6, 131.2, 133.9, 140.1, 142.5, 142.9, 144.5, 156.4, 
160.7; IR (KBr): 3301, 1681, 1595, 1482 cm−1; MS (EI): m/z 314 (M+); HRMS: calcd for 













8-Hydroxy-2-imino-2H-chromene-3-carboxylic acid (4-chlorophenyl)amide (13j). Yield: 
91%; mp: 272–273 °C; 1H-NMR (500 MHz, DMSO-d6) δ 7.07–7.11 (1H and 1H, each d), 
7.23 (1H, dd, J = 5.0, 2.5 Hz), 7.43 (2H, dd, J = 5.0, 2.0 Hz), 7.70 (2H, dd, J = 5.0, 2.0 Hz), 8.50 
(1H, d, J = 1.5 Hz), 9.11 (1H, s); 13C-NMR (125 MHz, DMSO-d6) δ 119.8, 120.2, 120.3, 
120.6, 121.7, 124.6, 128.1, 129.5, 137.7, 142.5, 142.7, 144.5, 156.4, 160.5; IR (KBr): 3302, 











8-Hydroxy-2-imino-2H-chromene-3-carboxylic acid benzylamide (13k). Yield: 55%; mp: 
206–208 °C; 1H-NMR (500 MHz, DMSO-d6) δ 4.53 (2H, d, J = 6.0 Hz), 7.04–7.08 (1H and 
1H, each d), 7.18 (1H, dd, J = 8.0, 6.0 Hz), 7.25–7.28 (1H, m), 7.32–7.36 (4H, m), 8.39 (1H, 
s), 8.82 (1H, s), 10.74 (1H, t, J = 6.0 Hz); 13C-NMR (125 MHz, DMSO-d6) δ 43.3, 119.9, 
120.4, 120.5, 124.4, 127.5, 127.9, 128.8, 129.0, 139.3, 141.9, 142.4, 144.4, 156.1, 162.2; IR 
(KBr): 3320, 1696, 1558, 1469 cm−1; MS (EI): m/z 294 (M+); HRMS: calcd for C17H14N2O3 














8-Hydroxy-2-imino-2H-chromene-3-carboxylic acid 2-hydroxybenzylamide (13l). Yield: 
62%; mp: 140–141 °C; 1H-NMR (500 MHz, DMSO-d6) δ 4.30 (2H, d, J = 6.0 Hz), 6.76 (1H, t, J 
= 7.0 Hz), 6.82 (1H, d, J = 7.0 Hz), 7.03–7.06 (1H and 1H, each d), 7.09 (1H, dd, J = 5.0, 2.5 
Hz), 7.17 (2H, dd, J = 7.0, 4.0 Hz), 8.38 (1H, s), 8.79 (1H, s), 10.66 (1H, t, J = 6.0 
Hz);13C-NMR (125 MHz, DMSO-d6) δ 39.4, 115.4, 115.6, 119.4,124.4, 125.7, 128.89, 128.94, 
129.6, 141.9, 144.4, 145.0, 148.7, 155.8, 161.1, 161.7, 162.1; IR (KBr): 3309, 1669, 1457, 1240 










8-Hydroxy-2-imino-2H-chromene-3-carboxylic acid 3-hydroxybenzylamide (13m). Yield: 
46%; mp: 205–207 °C; 1H-NMR (500 MHz, DMSO-d6) δ 4.44 (2H, d, J = 6.0 Hz), 6.64 (1H, 
dd, J = 6.0, 2.0 Hz), 6.69–6.74 (1H and 1H, d and s), 7.04–7.08 (1H and 1H, each d), 7.12 (1H, t, 
J = 8.0 Hz), 7.19 (1H, dd, J = 7.0, 4.0 Hz), 8.39 (1H, s), 8.82 (1H, br), 10.70 (1H, t, J = 5.5 Hz); 
13C-NMR (125 MHz, DMSO-d6) δ 43.2, 114.5, 114.7, 118.4, 119.8, 119.9, 120.4, 124.4, 
130.0, 140.7, 141.9, 142.4, 144.4, 156.1, 158.0, 162.1; IR (KBr): 3291, 1669, 1596, 1473 cm−1; 










8-Hydroxy-2-imino-2H-chromene-3-carboxylic acid 4-hydroxybenzylamide (13n). Yield: 
24%; mp: 187–188 °C; 1H-NMR (500 MHz, DMSO-d6) δ 4.38 (2H, d, J = 6.0 Hz), 6.72 (2H, d, 
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J = 8.0 Hz), 7.05–7.07 (1H and 1H, each d), 7.12 (2H, d, J = 8.0 Hz), 7.18 (1H, dd, J = 3.5, 3.0 
Hz), 8.39 (1H, s), 8.78 (1H, br), 10.61 (1H, t, J = 6.0 Hz); 13C-NMR (125 MHz, DMSO-d6) δ 
42.9, 115.5, 115.8, 119.9, 120.4, 120.6, 124.4, 129.4, 141.9, 142.4, 144.4, 156.1, 157.0, 160.6, 
161.9; IR (KBr): 3293, 1675, 1473, 1240 cm−1; MS (EI): m/z 310 (M+); HRMS: calcd for 










8-Hydroxy-2-imino-2H-chromene-3-carboxylic acid 2-chlorobenzylamide (13o). Yield: 
85%; mp: 258–259 °C; 1H-NMR (500 MHz, DMSO-d6) δ 4.59 (2H, d, J = 6.0 Hz), 7.04–7.08 
(1H and 1H, each d), 7.18 (1H, dd, J = 4.0, 3.0 Hz), 7.32–7.35 (2H, m), 7.41–7.43 (1H, m), 
7.47–7.49 (1H, m), 8.38 (1H, s), 8.84 (1H, s), 10.81 (1H, t, J = 6.0 Hz); 13C-NMR (125 MHz, 
DMSO-d6) δ 41.4, 119.8, 120.0, 120.37, 120.43, 124.5, 127.9, 129.5, 129.8, 129.9, 132.9, 
136.4, 142.1, 142.5, 144.4, 156.1, 162.3; IR (KBr): 3301, 1674, 1472, 1225 cm−1; MS (EI): m/z 










8-Hydroxy-2-imino-2H-chromene-3-carboxylic acid 3-chlorobenzylamide (13p). Yield: 
90%; mp: 229–230 °C; 1H-NMR (500 MHz, DMSO-d6) δ 4.53 (2H, d, J = 5.5 Hz), 7.04–7.08 
(1H and 1H, each d), 7.18 (1H, dd, J = 4.0, 3.0 Hz), 7.30 (1H, d-like, J = 7.0 Hz), 7.33 (1H, 
d-like, J = 7.0 Hz), 7.36–7.40 (2H, m), 8.39 (1H, s), 8.85 (1H, br), 10.77 (1H, t, J = 6.0 Hz); 
13C-NMR (125 MHz, DMSO-d6) δ 42.7, 119.8, 120.0, 120.4, 124.4, 126.6, 127.4, 127.5, 
127.7, 130.8, 133.6, 142.1, 142.2, 142.5, 144.5, 156.1, 162.4; IR (KBr): 3299, 1674, 1472, 1225 












8-Hydroxy-2-imino-2H-chromene-3-carboxylic acid 4-chlorobenzyl amide (13q). Yield: 
93%; mp: 241–242 °C; 1H-NMR (500 MHz, DMSO-d6) δ 4.53 (2H, d, J = 6.0 Hz), 7.03–7.08 
(1H and 1H, each d), 7.18 (1H, dd, J = 4.0, 2.5 Hz), 7.35 (2H, d, J = 7.0 Hz), 7.40 (2H, d, J = 
7.0 Hz), 8.39 (1H, s), 8.94 (1H, s), 10.75 (1H, t, J = 6.0 Hz); 13C-NMR (125 MHz, DMSO-d6) δ 
42.6, 119.8, 120.0, 120.4, 120.5, 124.4, 128.9, 129.8, 132.1, 138.6, 142.0, 142.5, 144.5, 156.2, 
162.3; IR (KBr): 3299, 1675, 1473, 1229 cm−1; MS (EI): m/z 328 (M+); HRMS: calcd for 











This compound was prepared by the same procedure as that for 13 but using 
2-hydroxy-3-methoxybenzaldehyde instead of 11.  
8-Methoxy-2-imino-2H-chromene-3-carboxylic acid (2-chlorophenyl) amide (15).Yield: 
98%; mp: 237–238 °C; 1H-NMR (500 MHz, DMSO-d6) δ 3.89 (3H, s), 7.16 (1H, t, J = 7.0 Hz), 
7.22 (1H, t, J = 7.0 Hz), 7.31 (1H, d, J = 7.0 Hz), 7.36–7.40 (3H, m), 7.53 (1H, d, J = 7.3 Hz), 
8.49 (1H, d, J = 7.3 Hz), 8.56 (1H, s), 9.36 (1H, br); 13C-NMR (125 MHz, DMSO-d6) δ 56.3, 
115.0, 119.0, 120.9, 121.2, 122.6, 124.0, 124.4, 124.8, 127.3, 129.3, 135.8, 142.6, 143.3, 146.3, 
156.8, 160.5; IR (KBr): cm−1 MS (EI): m/z 328 (M+); HRMS: calcd for C17H13ClN2O3 328.0615, 
Found: 328.0618. 
 
General procedure for the preparation of 14.  
10% HCl was added (5 drops) to a stirred solution of chromene 13 (1 mmol) in THF 
(5 mL), and the resulting mixture was kept at 40 °C for 24 h. The reaction was 
quenched by H2O (5 mL), and the aqueous mixture was extracted with EtOAc (5 mL × 
3), the organic extracts were collected, and dried over Na2SO4, and the solvent was 
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removed under reduced pressure. The residue was chromatographed on silica gel (15 g, 










8-Hydroxy-2-oxo-2H-chromene-3-carboxylic acid phenylamide (14a). Yield: 81%; mp: 
251–253 °C; 1H-NMR (500 MHz, DMSO-d6) δ 7.15 (1H, td, J = 7.5, 1.5 Hz), 7.24–7.28 (1H 
and 1H, each d), 7.37–7.42 (3H, m), 7.72 (2H, dd, J = 7.5, 1.5 Hz), 8.86 (1H, s), 10.50 (1H, br), 
10.69 (1H, s); 13C-NMR (125 MHz, DMSO-d6) δ 120.0, 120.1, 120.4, 120.6, 120.8, 124.8, 
125.8, 129.5, 138.5, 143.1, 145.0, 148.4, 160.4, 161.0; IR (KBr): 3424, 1707, 1598, 1472 cm−1; 











8-Hydroxy-2-oxo-2H-chromene-3-carboxylic acid (2-hydroxyphenyl)amide (14b). Yield: 
81%; mp: 224–226 °C; 1H-NMR (500 MHz, DMSO-d6) δ 6.83 (1H, td, J = 7.0, 1.5 Hz), 6.92 
(1H, dd, J = 7.0, 1.5 Hz), 6.97 (1H, td, J = 7.0, 1.5 Hz),7.25–7.28 (1H and 1H, each d), 7.45 (1H, 
dd, J = 4.0, 3.0 Hz), 8.39 (1H, dd, J = 7.0, 1.5 Hz), 8.99 (1H, s), 10.02 (1H, br), 10.51 (1H, br), 
11.14 (1H, br); 13C-NMR (125 MHz, DMSO-d6) δ 115.1, 119.0, 119.7, 120.1, 120.4, 120.7, 
120.9, 124.8, 125.7, 127.1, 143.2, 145.1, 147.2, 149.3, 159.4, 161.4; IR (KBr): 3177, 1718, 














8-Hydroxy-2-oxo-2H-chromene-3-carboxylic acid (3-hydroxyphenyl)amide (119c). Yield: 
83%; mp: 248–250 °C; 1H-NMR (500 MHz, DMSO-d6) δ 6.55 (1H, dd, J = 6.5, 1.5 Hz), 7.02 
(1H, dd, J = 6.5, 1.5 Hz), 7.16 (1H, t, J = 6.5 Hz), 7.24–7.28 (1H and 1H, each d), 7.32 (1H, t, J 
= 3.0 Hz), 7.41 (1H, dd, J = 4.5, 2.5 Hz), 8.84 (1H, s), 9.54 (1H, s), 10.49 (1H, br), 10.61 (1H, 
s); 13C-NMR (125 MHz, DMSO-d6) δ 107.3, 111.0, 111.9, 120.0, 120.2, 120.6, 120.8, 125.8, 
130.2, 139.5, 143.0, 145.0, 148.3, 158.3, 160.2, 161.0; IR (KBr): 3288, 1714, 1609, 1472 cm−1; 











8-Hydroxy-2-oxo-2H-chromene-3-carboxylic acid (4-hydroxyphenyl) amide (14d). Yield: 
52%; mp: 254–256 °C; 1H-NMR (500 MHz, DMSO-d6) δ 6.75 (2H, d, J = 6.5 Hz), 7.23–7.25 
(1H and 1H, each d, m), 7.39 (1H, dd, J = 5.0, 2.5 Hz), 7.50 (2H, d, J = 6.5 Hz), 8.83 (1H, s), 
9.36 (1H, s), 10.47 (1H, s), 10.48 (1H, br); 13C-NMR (125 MHz, DMSO-d6) δ 115.9, 120.00, 
120.03, 120.6, 120.7, 122.1, 125.7, 130.1, 143.0, 145.0, 148.2, 154.7, 159.7, 161.1; IR (KBr): 















8-Hydroxy-2-oxo-2H-chromene-3-carboxylic acid (2-fluorophenyl)amide (119e). Yield: 
98%; mp: 248–250 °C; 1H-NMR (500 MHz, DMSO-d6) δ 7.20 (1H, m), 7.25–7.29 (3H m), 7.36 
(1H, dd, J = 5.0, 2.5 Hz), 7.48 (1H, d, J = 6.5 Hz), 8.40 (1H, t, J = 6.5 Hz), 9.00 (1H, s), 10.53 
(1H, br), 11.08 (1H, br); 13C-NMR (125 MHz, DMSO-d6) δ 115.7 (d, J = 18.3 Hz), 118.7, 120.0, 
120.9, 121.2, 122.1, 125.4 (d, J = 2.4 Hz), 125.5 (d, J = 8.4 Hz), 125.9, 126.5 (d, J = 8.6 Hz), 
143.1, 145.1, 149.6, 152.9 (d, J = 241.9 Hz), 160.2, 161.7; IR (KBr): 3386, 1704, 1554, 1471 











8-Hydroxy-2-oxo-2H-chromene-3-carboxylic acid (3-fluorophenyl)-amide (14f). Yield: 
85%; mp: 247–249 °C; 1H-NMR (500 MHz, DMSO-d6) δ 6.99 (1H, tt, J = 6.5, 1.5 Hz), 7.26–
7.29 (1H and 1H, each d), 7.42–7.46 (3H, m), 7.78 (1H, dt, J = 6.5, 1.5 Hz), 8.86 (1H, s), 10.52 
(1H, br), 10.83 (1H, br); 13C-NMR (125 MHz, DMSO-d6) δ 107.3 (d, J = 23.8 Hz), 111.3 (d, J = 
23.8 Hz), 116.3, 119.9, 120.0, 120.6, 120.9, 125.8 (d, J = 1.25 Hz), 131.1 (d, J = 10.3 Hz), 140.1 
(d, J = 10.3 Hz), 143.1, 145.0, 148.6, 160.7, 160.8, 162.7 (d, J = 239.3 Hz); IR (KBr): 3436, 















8-Hydroxy-2-oxo-2H-chromene-3-carboxylic acid (4-fluorophenyl)amide (14g). Yield: 
89%; mp: 241–243 °C; 1H-NMR (500 MHz, DMSO-d6) δ 7.21–7.27 (4H, m), 7.41 (1H, dd, J = 
4.5, 2.5 Hz), 7.56 (2H, dd, J = 6.5, 4.5 Hz), 8.85 (1H, s), 10.70 (1H, br); 13C-NMR (125 MHz, 
DMSO-d6) δ 116.1 (d, J = 23.1 Hz), 119.9, 120.1, 120.6, 120.9, 122.3 (d, J = 8.5 Hz), 125.8 (d, 
J = 3.6 Hz), 134.9, 143.1, 145.1, 148.4, 159.1 (d, J = 239.4 Hz), 160.5, 160.8; IR (KBr): 3372, 












8-Hydroxy-2-oxo-2H-chromene-3-carboxylic acid (2-chlorophenyl)amide (14h). Yield: 
95%; mp: 286–287 °C; 1H-NMR (500 MHz, DMSO-d6) δ 7.20 (1H, td, J = 7.0, 1.5 Hz), 7.28–
7.29 (1H and 1H, each d), 7.42 (1H, td, J = 7.0, 1.5 Hz), 7.48 (1H, t, J = 5.5 Hz), 7.59 (1H, dd, J 
= 7.0, 1.5 Hz), 8.53 (1H, dd, J = 7.0, 1.0 Hz), 9.03 (1H, s), 10.56 (1H, br), 11.31 (1H, br); 
13C-NMR (125 MHz, DMSO-d6) δ 118.5, 120.0, 121.0, 121.3, 122.3, 123.3, 125.9, 128.5, 130.0, 
135.3, 137.7, 143.2, 145.1, 150.0, 160.3, 161.7; IR (KBr): 3200, 1733, 1473, 1202 cm−1; MS 














8-Hydroxy-2-oxo-2H-chromene-3-carboxylic acid (3-chlorophenyl)amide (14i). Yield: 47%; 
mp: 266–268 °C; H-NMR (500 MHz, DMSO-d6) δ 7.21 (1H, ddd, J = 7.0, 2.5, 1.0 Hz), 7.24–
7.28 (1H and 1H, each d), 7.38–7.42 (2H, m), 7.57 (1H, ddd, J = 7.0, 2.5, 1.0 Hz), 7.90 (1H, d, J 
= 2.0 Hz), 8.83 (1H, s), 10.78 (1H, s); 13C-NMR (125 MHz, DMSO-d6) δ 119.0, 119.8, 119.9, 
120.0, 120.6, 120.9, 124.5, 125.8, 131.2, 133.8, 139.9, 143.1, 145.0, 148.6, 160.6, 160.9; IR 
(KBr): 3238, 1733, 1604, 1473 cm−1; MS (EI): m/z 315 (M+); HRMS: calcd for C16H10ClNO4 











8-Hydroxy-2-oxo-2H-chromene-3-carboxylic acid (4-chlorophenyl)amide (14j). Yield: 
54%; mp: 299–300 °C; 1H-NMR (500 MHz, DMSO-d6) δ 7.24–7.28 (1H and 1H, each d), 7.41 
(1H, dd, J = 5.0, 2.5 Hz), 7.44 (2H, d, J = 7.0 Hz), 7.77 (2H, d, J = 7.0 Hz), 8.84 (1H, s), 10.76 
(1H, br); 13C-NMR (125 MHz, DMSO-d6) δ 119.9, 120.0, 120.5, 120.9, 122.0, 125.8, 128.4, 
129.4, 137.4, 143.1, 145.2, 148.5, 160.7, 160.8; IR (KBr): 3233, 1733, 1472, 1207 cm−1; MS 










8-Hydroxy-2-oxo-2H-chromene-3-carboxylic acid benzylamide (14k). Yield: 99%; mp: 262–
264 °C; 1H-NMR (500 MHz, DMSO-d6) δ 4.54 (2H, d, J = 6.0 Hz), 7.22–7.40 (8H, m), 8.82 
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(1H, s), 9.14 (1H, t, J = 6.0 Hz), 10.45 (1H, br); 13C-NMR (125 MHz, DMSO-d6) δ 119.3, 119.9, 
120.56, 120.62, 125.6, 127.4, 127.9, 128.9, 139.4, 143.1, 144.9, 148.5, 160.8, 161.8; IR (KBr): 











8-Hydroxy-2-oxo-2H-chromene-3-carboxylic acid 2-hydroxybenzylamide (14l). Yield: 
50%; mp: 256–257 °C; 1H-NMR (500 MHz, DMSO-d6) δ 4.47 (2H, d, J = 6.0 Hz), 6.76 (1H, td, 
J = 7.0, 0.5 Hz), 6.83 (1H, dd, J = 7.0, 0.5 Hz), 7.10 (1H, td, J = 7.0, 1.5 Hz), 7.19 (1H, dd, J = 
7.0, 1.5 Hz), 7.22–7.24 (1H and 1H, each d), 7.39 (1H, dd, J = 4.0, 2.5 Hz), 8.84 (1H, s), 9.16 
(1H, t, J = 6.0 Hz), 9.70 (1H, br), 10.45 (1H, br); 13C-NMR (125 MHz, DMSO-d6) δ 39.4, 115.6, 
119.0, 119.4, 120.0, 120.6, 120.7, 124.9, 125.6, 128.9, 129.6, 143.1, 145.0, 148.7, 155.8, 161.0, 
161.6; IR (KBr): 3315, 1685, 1555, 1293 cm−1; MS (EI): m/z 311 (M+); HRMS: calcd for 










8-Hydroxy-2-oxo-2H-chromene-3-carboxylic acid 3-hydroxybenzylamide (14m). Yield: 
81%; mp: 208–210 °C; 1H-NMR (500 MHz, DMSO-d6) δ 4.45 (2H, d, J = 6.0 Hz), 6.64 (1H, dd, 
J = 6.5, 2.5 Hz), 6.75 (1H, s), 6.77 (1H, d, J = 6.5 Hz), 7.12 (1H, t, J = 6.5 Hz), 7.21–7.26 (1H 
and 1H, each d), 7.39 (1H, dd, J = 5.0, 2.5 Hz), 8.82 (1H, s), 9.08 (1H, t, J = 6.0 Hz), 9.39 (1H, 
s), 10.47 (1H, br); 13C-NMR (125 MHz, DMSO-d6) δ 114.4, 114.7, 118.5, 119.3, 119.9, 120.6, 
120.7, 125.6, 129.9, 140.7, 143.1, 145.0, 148.6, 157.9, 160.8, 161.7; IR (KBr): 3320, 1700, 













8-Hydroxy-2-oxo-2H-chromene-3-carboxylic acid 4-hydroxybenzylamide (14n). Yield: 
99%; mp: 234–235 °C; 1H-NMR (500 MHz, DMSO-d6) δ 4.41 (2H, d, J = 6.0 Hz), 6.72 (2H, d, 
J = 8.0 Hz), 7.16 (2H, d, J = 8.0 Hz), 7.20–7.25 (1H and 1H, each d), 7.38 (1H, dd, J = 5.0, 2.0 
Hz), 8.82 (1H, s), 8.99 (1H, t, J = 6.0 Hz), 9.33 (1H, br), 10.44 (1H, br); 13C-NMR (125 MHz, 
DMSO-d6) δ 31.2, 42.9, 115.7, 119.3, 120.0, 120.60, 120.65, 125.65, 129.5, 143.1, 145.0, 148.5, 
157.0, 160.9, 161.6; IR (KBr): 3321, 1699, 1472, 12119cm−1; MS (EI): m/z 311 (M+); HRMS: 










8-Hydroxy-2-oxo-2H-chromene-3-carboxylic acid 2-chlorobenzylamide (14o). Yield: 71%; 
mp: 248–249 °C; 1H-NMR (500 MHz, DMSO-d6) δ 4.61 (2H, d, J = 6.0 Hz)7.22–7.26 (1H and 
1H, each d), 7.31–7.34 (2H, m), 7.39 (1H, dd, J = 4.0, 2.5 Hz), 7.42 (1H, dd, J = 7.0, 2.5 Hz), 
7.47 (1H, dlike, J = 7.0 Hz), 8.82 (1H, s), 9.21 (1H, t, J = 6.0 Hz), 10.45 (1H, br); 13C-NMR 
(125 MHz, DMSO-d6) δ 119.1, 119.9, 120.6, 120.7, 125.7, 127.8, 129.3, 129.5, 129.7, 132.6, 
136.4, 143.1, 145.0, 148.7, 160.9, 162.1; IR (KBr): 3329, 1701, 1470, 1248 cm−1; MS (EI): m/z 










8-Hydroxy-2-oxo-2H-chromene-3-carboxylic acid 3-chlorobenzylamide (14p). Yield: 90%; 
mp: 207–208 °C; 1H-NMR (500 MHz, DMSO-d6) δ 4.54 (2H, d, J = 6.0 Hz), 7.21–7.25 (1H and 
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1H, each d), 7.31–7.34 (2H, m), 7.37–7.39 (2H, m), 7.42 (1H, t-like, J = 2.0 Hz), 8.81 (1H, s), 
9.21 (1H, t, J = 6.0 Hz), 10.44 (1H, br); 13C-NMR (125 MHz, DMSO-d6) δ 42.7, 119.3, 119.9, 
120.6, 120.7, 125.6, 126.6, 127.4, 127.8, 130.7, 133.5, 142.3, 143.1, 145.0, 148.6, 160.7, 162.1; 
IR (KBr): 3334, 1696, 1472, 1211 cm−1; MS (EI): m/z 329 (M+); HRMS: calcd for C17H12ClNO4 










8-Hydroxy-2-oxo-2H-chromene-3-carboxylic acid 4-chlorobenzylamide (14q). Yield: 73%; 
mp: 269–270 °C; 1H-NMR (500 MHz, DMSO-d6) δ 4.52 (2H, d, J = 6.0 Hz), 7.20–7.25 (1H and 
1H, each d), 7.36–7.41 (5H, m, including at 7.39 (4H, d, J = 7.0 Hz)), 8.81 (1H, s), 9.18 (1H, t, J 
= 6.0 Hz), 10.45 (1H, br); 13C-NMR (125 MHz, DMSO-d6) δ 42.6, 119.3, 119.9, 120.6, 120.7, 
125.6, 128.8, 129.8, 132.0, 138.6, 143.1, 145.0, 148.6, 160.7, 162.0; IR (KBr): 3320, 1694, 




Preparation of recombinant enzymes. 
 The recombinant CBR1, CBR3, DHRS4, DCXR, AKR1B1, AKR1B10, AKR1C1, 
AKR1C4, and AKR1C2, were made and purified to homogeneity, as said previously. A 
Quick Change site-directed mutagenesis  kit (Stratagene, La Jolla, CA) was used to 
perform Site-directed mutagenesis and the pET28a expression plasmid harboring the 
cDNA for CBR1 as the template, according to the protocol described by the 
manufacturer. The primer pair prepared for the mutagenesis was through sense and 
antisense oligonucleotides to alter one codon of the cDNA. The 26- to 30-mer primers 
were composited to give the Met141Gln, Met141Val, Trp229Phe and Trp229Leu 
mutant enzymes (ESI Table S1†). The coding area of the cDNAs in the expression 
plasmids were arranged using a Beckman CEQ8000XL DNA sequencer aim to confirm 
the presence of the desired mutationand ensure that no other mutation had occurred. The 
expression constructs were changed into Escherichia coli BL21 (DE3) pLysS cells (Life 
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Technologies, Carlsbad, CA). The mutant enzymes were expressed in Escherichia coli 
cells, and purified to homogeneity as said above for the wild-type CBR1. 
 
Assay of enzyme activity. 
   The reductase and dehydrogenase activities of CBR1 were assayed at 25 °C by 
testing the rate of change in NADPH absorbance (at 340 nm) and fluorescence (at 455 
nm with an excitation wavelength of 340 nm), respectively. The IC50 values for 
inhibitors were determined in the reaction system that consisted of 0.1 M potassium 
phosphate buffer, pH 7.0, 0.1 mM NADPH, substrate and enzyme, in a total volume of 
2.0 mL. The substrates for CBR1 were 50 μM isatin, 0.1 mM menadione (for CBR3), 
for DCXR were 0.4 mM diacetyl, 25 μM 1-phenylisatin (for DHRS4) and 0.2 mM 
pyridine-3-aldehyde (for AKR1B10 and AKR1B1). The dehydrogenase activity of 
CBR1 was tested using 0.25 mM NADP+ and an appropriate amount of S-tetralol as the 
coenzyme and the substrate, respectively, in the above reaction system. The kinetic 
studies in the presence of inhibitors were carried out in not only isatin reduction but also 
S-tetralol oxidation over a range of 5 or 6 substrate concentrations at the above 
saturating concentration of NADPH or NADP+. The inhibition patterns were determined 
from the Lineweaver–Burk plots, and inhibition constants, Ki (slope effect) and K′i 
(intercept effect), were judged from replots of the slopes and intercepts, respectively, 
versus inhibitor concentration. The IC50 and Ki values are showed as the means ± SD 
for at least three determinations.  
 
Molecular modeling. 
All calculations were carried out using the Schrödinger suite 2013-2 (Schrödinger, LLC, 
New York, NY). Using the LigPrep2.7 program the 2D structure of 13h was first 
changed into the 3D structure. The protonation states of the compounds were predicted 
using the Epik2.5 program. Then, the conformational search of  the compound was 
performed using the ConfGen2.5 program, and the resulting conformers were used in 
the following docking calculations. In the docking calculations, a total of five X-ray 
structures of CBR1 with the following PDB codes were used in order to consider 
protein flexibility as much as possible: 1WMA, 2PFG, 3BHI, 3BHJ, and 3BHM. 
Protein Preparation Wizard in Maestro9.5 helped to make The structures. The missing 
atoms for side chains were compensated for using the Prime3.3 program. Finally, 
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force-field OPLS 2005 minimized the structures. We removed all HETATM molecules 
except NADP+ (i.e. ligands, ions, and water molecules) before docking calculations. 
The docking calculation of 13h against five X-ray structures of CBR1 was carried out 
using the IFD 2006 protocol as implemented in Schrödinger suite 2013-2.47 The box 
area for the “Receptor Grid Generation” protocol was set to a centroid of Ser139, 
Met141, Trp229, and Ala235 of CBR1, which were residues carrying the active site. 
Initial Glide docking was performed using reduced van der Waals radii for proteins and 
ligands to allow minor readjustments. The van der Waals radii of both molecules were 
tested by 80%. The maximum number of poses per conformer was set to 2. Re-docking 
was carried in Glide using standardsettings. The generated poses were ranked according 
to IFDScore, and we finally selected a pose with the lowest IFDScore as the interaction 
model. In order to validate our procedure, we suggested it for the hydroxy-PP–CBR1 
complex. The resulting model, i.e., the top-ranked pose, reproduced all interactions 
between hydroxy-PP and CBR1 showed in the crystal structure. The positional and 
conformational RMSDs were 0.48 and 0.13 Å, respectively. These results told that our 
procedure is appropriate forproducing reliable interaction models of 13h as well as 
hydroxy- PP. The docked model performed in Fig. 2 was generated using PyMOL 
(DeLano Scientific, San Carlos, CA, USA).  
 
Cell culture experiments.  
BAEC were taken from Dr Junichi Nakagawa (Tokyo University of Agriculture, 
Abashiri, Japan). The cells were trained in Dulbecco’s modified Eagle’s medium 
(DMEM) supplemented with 10% fetal bovine serum, 100 U mL−1 penicillin and 100 
μg mL−1 streptomycin at 37 °C in a humidified incubator containing 5% CO2. the 
cDNA for the enzyme was zoomed by PCR from the bacterial expression vector6 using 
primers aimed to overexpress CBR1 in the cells (ESI Table S1†). The amplified cDNA 
was subcloned at the EcoRI and SalI sites into the mammalian pGW1 expression vector, 
and the sequence of the insert was tested by DNA sequencing. The pGW1 expression 
vector harboring the cDNA for CBR1 was transfected into BAEC using Lipofectamine 
2000 (Invitrogen, Carlsbad, CA) when the cells were grown to 80% confluence in 
microplates. The empty vector was likely transfected into the cells, which were used as 
control cells. The transfection efficacy was evaluated by Western blotting using the 
antibodies against CBR148 and human β-actin (Santa Cruz Biotechnology, Santa Cruz, 
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CA), of which β-actin was used as a loading control. After 48 h culture, the cells were 
cleaned with DMEM twice containing 2% fetal bovine serum and the antibiotics, and 
then trained for  24h with 9,10-PQ. In the experiments with 13h and 13p, the cells 
were pretreated with or without the inhibitors 2h before the training of 5 μM 9,10-PQ. 
Dimethylsulfoxide    was the vehicle of the agents.  The cell   viability was tested 
by the tetrazolium dye-based cytotoxicity assay using 
2-(4-iodophenyl)-3-(4-nitrophenyl)-5-(2, 4-disulfophenyl)-2H- tetrazolium. Data are 
expressed as means ± SD for not less than three independent experiments. Statistical 
evaluation of the data was carried out using the unpaired Student’s t-test and ANOVA 





























Melting points were tested with an ASONE micro melting point apparatus and are not 
corrected. Flash chromatography was performed with Kanto Kagaku silica gel 60N 
(63−210 mm). Chemical shifts (δ) are given in ppm downfield from TMS and 
referenced to CHCl3 (7.26 ppm) or DMSO (2.50 ppm) for 1H-NMR spectra and the 
centre line of CDCl3 (77.0 ppm) for 13C-NMR spectra as an internal standard. Peak 
multiplicities are decided by the following abbreviations: s, singlet; d, doublet; t, triplet; 
q, quartet; m, multiplet; br, broad and coupling constants in (J) Hz. High-resolution 
mass spectral data were tested by a JEOL MStation JMS-700. All commercial reagents 
were used as received unless otherwise noted. Infrared spectra were tested with a 
SHIMADZU FTIR-8400 spectrometer using film KBr pellet technique. The purities (91 
to >98%) of compounds 18a′ and 19a−l were analyzed by HPLC analysis. Analytical 
HPLC carried out on JASCO PU-2082 plus intelligent HPLC pump with GL Science 
InertSustainC18 (5 μL, 4.6 mm × 250 mm) column and 100% MeCN as mobile phase 
with flow rate of 1−3 mL/min at 35−50°C.   
 
General Procedure for the Preparation of Methanesulfonic Acid Ester (B).  
MsCl (1.2 mmol) and Et3N (1.5 mmol) were added to a stirred solution of the alcohol 
(A1, A2, A3,A4, or A5, 1 mmol) in CH2Cl2 (5 mL) at 0 °C, and the resulting mixture 
was stirred for 2 h at 25oC. The reaction was quenched by satd. NH4Cl (aq), and the 
organic layer was separated. The aqueous mixture was extracted with CH2Cl2 (5 mL × 
3), and the organic layer and extracts were collected, dried over Na2SO4, and 
evaporated. The residue was chromatographed on silica gel (15 g, hexane/ethyl 
acetate = 4:1) to give the pure methanesulfonic acid ester B, which was immediately 









Methanesulfonic Acid 3-(3-Methoxymethoxyphenyl)propyl Ester (B1). Yield :96%; 1H 
NMR (500 MHz, CDCl3) δ 2.08 (2H, quint, J =7.5 Hz), 2.73 (2H, t, J = 7.5 Hz), 3.00 (3H, s), 
3.48 (3H, s), 4.23 (2H, t, J = 7.5 Hz), 5.17 (2H, s), 6.83−6.91 (3H, m), 7.21 (1H, t, J = 8.0 Hz); 






Methanesulfonic Acid 3-(2-Methoxymethoxyphenyl)propyl Ester (B2). Yield : 94%; 1H 
NMR (500 MHz, CDCl3) δ 1.82 (2H, quin, J = 7.5 Hz), 2.71 (2H, t, J = 7.5 Hz), 3.15 (2H, t, J 
= 7.5 Hz), 3.49 (3H, s), 5.21 (2H, s), 6.84 (1H, t, J = 8.0 Hz), 7.08 (1H,d, J = 8.0 Hz), 
7.10−7.17 (1H, m); 13C NMR (125 MHz, CDCl3) δ 30.4, 31.9, 38.2, 55.8, 94.1, 113.5, 121.2, 





Methanesulfonic Acid 3-(4-Methoxymethoxyphenyl)propyl Ester (B3). Yield :96%; 1H 
NMR (500 MHz, CDCl3) δ 1.88 (2H, quint, J = 7.3 Hz), 2.65 (2H, t, J = 7.3 Hz), 3.28 (2H, t, J 
= 7.3 Hz), 3.48 (3H, s), 5.18 (2H, s), 6.97 (2H, d, J = 8.0 Hz), 7.09(2H, d, J = 8.0 Hz); 13C 









Methanesulfonic Acid 4-(4-Methoxymethoxyphenyl)butyl ester (B4). Yield : 96%; 1H 
NMR (500 MHz, CDCl3) δ 1.69−1.78 (4H, m), 2.60 (2H, t, J = 7.5 Hz), 2.98 (3H, s), 3.48 (3H, 
s), 4.23 (2H, t, J = 7.5 Hz), 5.15 (2H, s), 6.96 (2H, d, J = 8.5 Hz), 7.08 (2H, d, J = 8.5 Hz); 







Methanesulfonic Acid 3-(3-Fluorophenyl)propyl Ester (B5). Yield: 78%; 1H NMR (500 
MHz, CDCl3) δ 2.89 (2H, quint, J = 7.5 Hz), 3.11 (2H, t, J = 7.5 Hz), 3.35 (3H, s), 4.58 (2H, t, 
J = 7.5 Hz), 7.11−7.25 (3H, m), 7.61 (2H,d, J = 7.5 Hz); 13C NMR (125 MHz, CDCl3) δ 29.7, 
30.5, 68.8, 112.31 (d, J = 19.4 Hz), 114.6 (d, J = 18.3 Hz), 123.7, 129.5 (d, J = 7.3 Hz), 142.5 
(d, J = 9.6 Hz), 162.2 (d, J = 241.7Hz). 
 
General Procedure for the Preparation of Azide (C).  
To a stirred solution of methanesulfonic acid ester (B1, B2, B3, B4, B5, or B6, 1 
mmol) in DMF/H2O (2:1) was added NaN3 (2 mmol), and then the reaction mixture 
was heated to 60 °C for 20 h. After cooling, the reaction was quenched by H2O. The 
aqueous mixture was extracted with CH2Cl2 (5 mL × 3). The organic extracts were 
combined, dried over Na2SO4, and evaporated. The residue was chromatographed on 
silica gel (15 g, hexane/acetone = 100:1) to give the corresponding azide C, which 






1-(3-Azidopropyl)-3-methoxymethoxybenzene (C1). Yield: 78%; 1H NMR (500 MHz, 
CDCl3) δ 1.92 (2H, quint, J = 7.5 Hz), 2.68 (2H, t, J = 7.5 Hz), 3.29 (2H, t, J = 7.5 Hz), 3.49 
(3H, s), 5.17 (2H, s), 6.83−6.90 (3H, m), 7.21 (1H, t, J = 8.0 Hz); 13C NMR (125 MHz, 
CDCl3) δ 30.2, 32.6, 50.5, 55.9, 94.3, 113.8, 116.3, 121.9, 129.4, 142.4, 157.3; IR (neat) 2422, 







1-(3-Azidopropyl)-2-methoxymethoxybenzene (C2). Yield: 89%; 1H NMR (500 MHz, 
CDCl3) δ 1.91 (2H, quint, J = 7.5 Hz), 2.73 (2H, t, J = 7.5 Hz), 3.29 (2H, t, J = 7.5 Hz), 3.49 
(3H, s), 5.21 (2H, s), 6.94 (1H, t, J = 8.0 Hz), 7.09 (1H,d, J = 8.0 Hz), 7.13−7.18 (1H, m); 13C 
NMR (125 MHz, CDCl3) δ 27.4, 28.9, 50.7, 55.8, 94.1, 113.7, 121.48, 127.3, 129.7, 123.0, 





1-(3-Azidopropyl)-4-methoxymethoxybenzene (C3). Yield: 94%; 1H NMR (500 MHz, 
CDCl3) δ 1.91 (2H, quint, J = 7.3 Hz), 2.73 (2H, t, J = 7.3 Hz), 3.29 (2H, t, J = 7.3 Hz), 3.49 
(3H, s), 5.21 (2H, s), 6.94 (1H, t, J = 8.0 Hz), 7.09 (1H,d, J = 8.0 Hz), 7.10−7.18 (1H, m); 13C 
NMR (125 MHz, CDCl3) δ 30.3, 31.6, 50.3, 55.6, 94.3, 116.1, 129.13, 133.9, 155.5; IR (neat) 






1-(4-Azidobutyl)-4-methoxymethoxybenzene (C4). Yield: 81%; 1H NMR (500 MHz, 
CDCl3) δ 1.62−1.68 (4H, m), 2.59 (2H, t, J = 7.5 Hz), 3.28 (2H, t, J = 7.5 Hz), 3.48 (3H, s), 
5.15 (2H, s), 6.96 (2H, dd, J = 4.5, 2.0 Hz), 7.08 (2H, dd, J = 4.5, 2.0 Hz); 13C NMR (125 
MHz, CDCl3) δ 28.4, 28.6, 34.5, 51.3, 55.9, 94.6, 116.3, 129.3, 135.2, 155.5; IR (neat) 2384, 






1-(3-Azidopropyl)-3-fluorobenzene (C5). Yield: 72%; 1H NMR (500 MHz, CDCl3) δ 1.90 
(2H, quint, J = 7.5 Hz), 2.71 (2H, t, J = 7.5 Hz), 3.29 (2H, t, J = 7.5 Hz), 6.82−6.95 (3H, m), 
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7.25 (2H, q, J = 7.0 Hz); 13C NMR (125 MHz, CDCl3) δ 29.9, 32.2, 50.2, 112.8 (d, J = 20.6 
Hz), 115.0 (d, J = 20.75 Hz), 123.9, 129.7 (d, J = 7.4 Hz), 143.3 (d, J = 7.3 Hz), 162.8 (d, J = 





1-(3-Azidopropyl)-4-methylbenzene (C6). Yield: 75%; 1H NMR (500 MHz, CDCl3) δ 1.90 
(2H, quint, J = 7.5 Hz), 2.33 (3H, s), 2.67 (2H, t, J = 7.5 Hz), 3.28 (2H, t, J = 7.5 Hz), 7.09 
(2H, d, J = 8.7 Hz); 13C NMR (125 MHz, CDCl3) δ20.5, 30.2, 31.9, 50.1, 127.9, 128.8, 135.0, 
137.4; IR (neat) 2385, 1652, 1635 cm−1. 
 
General Procedure for the Preparation of Amide (17a−i).  
A stirred suspension of C1, C2, C3, C4, C5, C6, C7, C8, or C9 (1mmol) and 10% 
Pd/C (3 mg) in MeOH (5 mL) was hydrogenated under hydrogen atmosphere (1 atm.) 
for overnight. The catalyst was removed, and the filtrate was evaporated to give the 
pure amine (16a−i), which was used in the next step directly. the corresponding amine 
(16a−i, 1 mmol), EDC (2 mmol), and DMAP (0.2 mmol)were added to a stirred 
solution of cyanoacetic acid (1 mmol) in CH2Cl2 (5 mL), and the resulting mixture was 
stirred at 25oC for 20 h. The reaction mixture was evaporated, and the residue was 
chromatographed on silica gel (15 g, hexane/acetone = 5:1) to give the corresponding  










2-Cyano-N-[3-(3-methoxymethoxyphenyl)propyl]acetamide (17a). Yield: 54%; 1H NMR 
(500 MHz, CDCl3) δ 1.90 (2H, quint, J = 7.5 Hz), 2.65 (2H, t, J = 7.5 Hz), 3.32 (2H, s), 3.34 
(2H, q, J = 7.5 Hz), 3.48 (3H, s), 5.17 (2H, s), 6.82−6.90 (3H, m), 7.22 (1H, t, J = 8.0 Hz); 
13C NMR (125 MHz, CDCl3) δ 25.7, 30.3, 33.0, 39.9, 55.9, 94.3, 113.9, 114.8, 116.2, 121.8, 
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129.5, 142.6, 157.3, 161.2; IR (neat) 3421, 1652, 1635 cm−1; MS (EI) m/z 262 (M+); HRMS 







2-Cyano-N-[3-(2-methoxymethoxyphenyl)propyl]acetamide  (17b). Yield: 70%; mp 
80−83 °C; 1H NMR (500 MHz, CDCl3) δ 1.86 (2H, quint, J = 7.0 Hz), 2.72 (2H, t, J = 7.0 Hz), 
3.33 (4H, q, J = 7.0 Hz), 3.49 (3H, s), 5.25 (2H, s), 6.39 (1H, br), 6.96 (1H, t, J = 8.0 Hz), 
7.09(2H,d, J = 8.0 Hz), 7.14−7.18(2H,m); 13C NMR (125 MHz, CDCl3) δ 25.6, 27.1, 29.2, 30.8, 
56.0, 94.4, 113.9, 114.8, 121.7, 127.3, 129.9, 129.9, 154.8, 161.2; IR (KBr) 3294, 1653, 1559 








2-Cyano-N-[3-(4-methoxymethoxylphenyl)propyl]acetamide (17c). Yield: 49%; mp 
78−81 °C; 1H NMR (500 MHz, CDCl3) δ 1.86 (2H, quint, J = 7.3 Hz), 2.62 (2H, t, J = 7.3 Hz), 
3.32 (4H, q, J = 7.3 Hz), 3.47 (3H, s), 5.15 (2H, s), 6.03 (1H, br), 6.97 (2H, d, J = 8.5 Hz), 
7.09 (2H,d, J = 8.5 Hz); 13C NMR (125 MHz, CDCl3) δ 25.7, 30.6, 32.1, 39.8, 55.8, 94.4, 
114.8, 116.3, 129.1, 134.3, 155.4, 161.3; IR (KBr) 3420, 1652, 1558 cm−1; MS (EI) m/z 262 









2-Cyano-N-[3-(3-fluorophenyl)propyl]acetamide (17d). Yield: 58%; mp 68−69 °C; 1H 
NMR (500 MHz, CDCl3) δ 1.89 (2H, quint, J = 7.5 Hz), 2.67 (2H, t, J = 7.5 Hz), 3.32−3.36 
(4H, m), 6.10 (1H, br), 6.90−6.96 (3H, m), 7.26 (1H, m); 13C NMR (125 MHz,CDCl3) δ 
25.7, 30.0, 32.4, 39.4, 112.6 (d, J = 20.6 Hz), 114.8 (d, J = 20.8 Hz), 123.8 (d, J = 2.5 Hz), 
129.6 (d, J = 8.5 Hz), 143.5 (d, J = 7.3 Hz), 161.2 (d, J = 6.1 Hz), 162.5 (d, J = 243.0 Hz); IR 
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(KBr) 3328, 1661, 1554 cm−1; MS (EI) m/z 220 (M+); HRMS Calcd for C12H13FN2O 







2-Cyano-N-[3-(4-fluorophenyl)propyl]acetamide (17e). Yield: 42%; mp 73−75 °C; 1H 
NMR (500 MHz, CDCl3) δ 1.87 (2H, quit, J = 7.5 Hz), 2.64 (2H, t, J = 7.5 Hz), 3.30−3.36 (4H, 
m), 6.96−7.00 (2H, m), 7.12−7.15 (2H, m); 13C NMR (125 MHz, CDCl3) δ 25.7, 30.5, 30.7, 
32.8, 39.6, 114.8 (d, J = 3.6 Hz), 115.0, 128.2 (d, J = 19.5 Hz), 129.4 (d, J = 7.3 Hz Hz), 136.6 
(d, J = 2.5 Hz), 161.0 (d, J = 242.0 Hz), 161.7; IR (KBr) 3323, 1660, 1587, 1554 cm−1; MS 









2-Cyano-N-[3-(3,5-difluorophenyl)propyl]acetamide (17f). Yield: 48%; mp 100−102 °C; 
1H NMR (500 MHz, DMSO-d6) δ 1.70 (2H, quint, J = 7.5 Hz), 2.60 (2H, t, J = 7.5 Hz), 3.60 
(2H, q, J = 7.5 Hz), 3.60 (2H, s), 6.94−7.03 (3H, m), 8.24 (1H, br); 13C NMR (125 MHz, 
CDCl3) δ 26.0, 30.3, 32.9, 39.8, 101.7 (t, J = 25.5 Hz), 111.1 (d, J = 4.8 Hz), 111.2 (d, J = 4.8 
Hz), 115.0, 145.0 (t, J = 8.5 Hz), 162.3, 163.1 (d, J = 248 Hz), 163.2 (d, J = 247.0 Hz); IR (KBr) 









2-Cyano-N-(3-p-tolylpropyl)acetamide (17g). Yield: 66%; mp 69−71 °C; 1H NMR (500 MHz, 
CDCl3) δ 1.88 (2H, quint, J = 7.5 Hz), 2.32 (3H, s), 2.64 (2H, t, J = 7.5 Hz), 3.34(4H, q, J = 
7.5 Hz), 7.11 (2H, q, J = 7.83 Hz); 13C NMR (125 MHz, CDCl3) δ 20.6, 25.6, 30.3, 32.2, 
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39.6, 115.0, 127.9, 128.8, 135.2, 137.7, 161.9; IR (KBr) 3295, 1652, 1558 cm−1; MS (EI) m/z 








2-Cyano-N-[3-(4-methoxyphenyl)propyl]acetamide (17h). Yield: 45%; mp 61−62 °C; 1H 
NMR (500 MHz, CDCl3) δ 1.88 (2H, quint, J = 7.5 Hz), 2.62 (2H, t, J = 7.5 Hz), 3.31 (2H, s), 
3.33 (2H, q, J = 7.5 Hz), 3.80 (3H, s), 5.99 (1H, br), 6.84 (2H, d, J = 9.0 Hz), 7.10 (2H, d, J 
= 9.0 Hz); 13C NMR (125 MHz, CDCl3) δ 25.7, 30.6, 31.9, 39.7, 55.0, 113.7, 114.9, 129.0, 
132.9, 157.7, 161.6; IR (KBr) 3355, 1655, 1559, 1516 cm−1; MS (EI) m/z 232 (M+); HRMS 









2-Cyano-N-[4-(4-methoxymethoxyphenyl)butyl]acetamide (17i). Yield: 49%; mp 59−60 °C; 
1H NMR (500 MHz, CDCl3) δ 1.56− 1.65 (4H, m), 2.59 (2H, t, J = 7.5 Hz), 3.32 (2H, q, J = 
7.5 Hz), 3.35 (2H, s), 3.45 (3H, s), 5.15 (2H, s), 6.05 (1H, br), 6.97 (2H, d, J = 8.5 Hz), 7.07 
(2H, d, J = 8.5 Hz); 13C NMR (125 MHz, CDCl3) δ 25.7, 28.47, 28.50, 34.3, 40.0, 55.7, 94.4, 
114.8, 116.1, 129.1, 135.2, 155.2, 161.3; IR (KBr) 3448, 1653, 1558, 1507 cm−1; MS (EI) 
m/z 276 (M+); HRMS Calcd for C14H18N2O3 276.1474, Found 276.1474. 
 
To a stirred solution of 17a (262 mg, 1 mmol) in THF (5 mL) was added 10% 
HCl (5 drops), and the resulting mixture was heated at 40 °C for 12 h. After cooling, 
H2O was added to the reaction mixture, and the aqueous mixture was extracted with 
EtOAc (5 mL × 3). The organic extracts were combined, dried over Na2SO4, and 
evaporated. The residue was chromatographed on silica gel (15 g, CH2Cl2/MeOH = 











2-Cyano-N-[3-(3-hydroxyphenyl)propyl]acetamide (17a′).1H NMR (400 MHz, CDCl3) δ 
1.89 (2H, q, J = 7.7 Hz), 2.63 (2H, t, J = 7.7 Hz), 3.32 (2H, s), 3.34 (2H, t, J = 7.7 Hz), 6.09 
(1H, br), 6.68 (1H, s), 6.69 (1H, d, J = 7.3 Hz), 6.75 (1H, d, J = 7.3 Hz), 7.16 (1H, t, J = 7.3 
Hz); 13C NMR (125 MHz, DMSO-d6) δ 25.3, 30.4, 32.4, 38.7, 112.8, 115.2, 116.3, 118.9, 
129.2, 142.9, 157.3, 162.0; IR (KBr) 3387, 1649, 1556 cm−1; MS (EI) m/z 218 (M+); HRMS 
Calcd for C12H14N2O2 218.1055, Found 218.1050. 
 
General Procedure for the Preparation of Amide (18a−k). 
Catalytic amount of piperidine (2 drops) and benzaldehyde (1 mmol)were added to 
a stirred solution of amide (17a−i, 1 mmol) in EtOH (3 mL), and the reaction mixture 
was stirred at 25oC for 12 h. The suspension was filtered to give iminochromene, 
which was used in the next step directly. To a stirred solution of the iminochromene 
obtained above in acetic acid (2 mL) was added pmethoxyaniline (1 mmol), and the 
resulting mixture was stirred at 25 oC for overnight. The solvent was removed under 
reduced pressure, and the residue was chromatographed on silica gel (15 g, 











7-Hydroxy-2-(4-methoxyphenylimino)-2H-chromene-3-carboxylic Acid [3-(3-Methoxy- 
methoxyphenyl)propyl]amide (18a). Yield: 67%; mp 144−146 °C; 1H NMR (500 MHz, 
CDCl3) δ 1.96 (2H, quint, J = 7.5 Hz), 2.70 (2H, t, J = 7.5 Hz), 3.45−3.50 (5H, m), 3.82 (3H, 
s), 5.13 (2H, s), 6.65 (1H, s), 6.75 (1H, d, J = 7.5 Hz), 6.82−6.94 (4H, m), 7.14−7.18 (1H, m), 
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7.25−7.27 (3H, m), 7.30 (1H, d, J = 7.5 Hz), 8.42 (1H, s), 10.75 (1H, br); 13C NMR (125 
MHz, CDCl3) δ 30.9, 33.4, 39.6, 55.5, 56.1, 94.5, 102.4, 111.8, 113.4, 113.8, 114.1, 116.5, 
122.2, 124.8, 129.5, 130.8, 137.3, 141.4, 143.1, 148.8, 155.3, 156.8, 157.4, 161.8, 162.5, 
163.8, 171.8; IR (KBr) 3442, 1653, 1559, 1506 cm−1; MS (EI) m/z 488 (M+); HRMS Calcd 











7-Hydroxy-2-(4-methoxyphenylimino)-2H-chromene-3-carboxylic Acid [3-(3-Hydroxy-  
phenyl)propyl]amide (18a′). Yield: 65%; mp 235−236 °C; 1H NMR (500 MHz, DMSO-d6) 
δ 1.80 (2H, quint, J = 7.6 Hz), 2.57 (2H, t, J = 7.6 Hz), 3.29−3.30 (2H, m), 3.77 (3H, s), 6.53 
(1H, d, J = 2.3 Hz), 6.56 (1H, dd, J = 8.3, 2.3 Hz), 6.59 (1H, s), 6.60 (1H, d, J = 8.9 Hz), 6.72 
(1H, dd, J = 8.3, 2.3 Hz), 6.95 (2H, d, J = 8.6 Hz), 7.04 (1H, t, J = 8.3 Hz), 7.32 (2H, d, J = 8.6 
Hz), 7.60 (1H, d, J = 8.9 Hz), 8.39 (1H, s), 9.24 (1H, br), 10.22 (1H, t, J = 5.6 Hz); 13C 
NMR (125 MHz, DMSO-d6) δ 31.1, 33.2, 39.0, 55.7, 101.8, 111.5, 113.3, 113.5, 114.5, 115.7, 
117.5, 119.5, 125.3, 129.8, 131.7, 137.5, 141.1, 143.3, 148.9, 155.1, 156.8, 157.9, 162.2, 
162.9; IR (KBr) 3190, 1666, 1566, 1448 cm−1; MS (EI) m/z 444 (M+); HRMS calcd for 













7-Hydroxy-2-(4-methoxyphenylimino)-2H-chromene-3-carboxylic Acid [3-(2-Methoxy- 
methoxyphenyl)propyl]amide (18b). Yield: 63%; mp 198−199 °C; 1H NMR (500 MHz, 
CDCl3) δ 1.95 (2H, quint, J = 7.5 Hz), 2.77 (2H, t, J = 7.5 Hz), 3.41 (3H, s), 3.50 (2H, q, J = 
7.5 Hz), 3.83 (3H, s), 5.13 (2H, s), 6.65 (1H, d, J = 2.5 Hz), 6.74 (1H, dd, J = 6.0, 2.5 Hz), 
6.89−6.92 (3H, m), 7.05 (1H, d, J = 8.0 Hz), 7.12−7.16 (2H, m), 7.26−7.29 (3H, m), 7.33 (1H, 
d, J = 8.5 Hz), 8.44 (1H, s), 10.68 (1H, t, J = 5.5 Hz); 13C NMR (125 MHz, CDCl3) δ 27.9, 
29.5, 39.6, 55.4, 55.9, 56.0, 94.2, 102.3, 107.1, 111.8, 113.2, 113.8, 114.0, 121.7, 124.7, 127.3, 
129.6, 130.1, 130.3, 130.6, 137.2, 141.2, 155.09, 155.12, 156.7, 163.5; IR (KBr) 3348, 1652, 











7-Hydroxy-2-(4-methoxyphenylimino)-2H-chromene-3-carboxylic Acid [3-(4-Methoxy- 
methoxyphenyl)propyl]amide (18c). Yield: 76%; mp 100−103 °C; 1H NMR (500 MHz, 
DMSO-d6) δ 1.93 (2H, quint, J = 7.5 Hz), 2.68 (2H, t, J = 7.5 Hz), 3.35−3.46 (5H,m), 3.84 
(3H, s), 5.13 (2H, s), 6.61 (1H, s), 6.70 (2H, d, J = 8.5 Hz), 6.93 (4H, t, J = 8.5 Hz), 7.11 (2H, 
d, J = 8.5 Hz), 7.37 (1H, d, J = 8.5 Hz), 7.62 (1H, d, J = 8.5 Hz), 8.42−8.50 (1H, m), 10.50 
(1H, t, J = 4.75 Hz); 13C NMR (125 MHz, DMSO-d6) δ; 31.0, 32.4, 39.3, 55.4, 55.9, 88.6, 
94.5, 102.3, 113.2, 114.0, 116.3, 124.6, 129.4, 130.7, 134.7, 141.2, 148.6, 155.2, 155.5, 156.7, 
161.9, 163.6, 177.9; IR (KBr) 3443, 1653, 1559, 1507 cm−1; MS (EI) m/z 488 (M+); 













7-Hydroxy-2-(4-methoxyphenylimino)-2H-chromene-3-carboxylic Acid [3-(3-Fluoro- 
phenyl)propyl]amide (18d). Yield 75%; mp 208− 210 °C; 1H NMR (500 MHz, DMSO-d6) δ 
1.85 (2H, quint, J = 7.5 Hz), 2.68 (2H, t, J = 7.5 Hz), 3.17−3.29 (2H, m), 3.77 (3H, s), 6.53 
(1H, s), 6.72 (1H, dd, J = 2.0, 8.5 Hz), 6.84−6.97 (3H, m), 7.05 (2H, d, J = 8.5 Hz), 7.30 (3H, 
d, J = 8.5 Hz), 7.60 (1H, d, J = 8.5 Hz), 8.38 (1H, s), 10.21 (1H, t, J = 5.5 Hz); 13C NMR (125 
MHz, DMSO-d6) δ 30.9. 32.8, 38.9, 55.8, 101.9, 111.5, 113.1 (d, J = 20.6 Hz), 113.5, 114.5, 
115.5, 115.6, 117.5, 125.0 (d, J = 2.5 Hz), 125.2, 130.7 (d, J = 8.5 Hz), 131.7, 137.5, 141.1, 
145.0 (d, J = 7.38 Hz), 148.9, 155.1, 156.8, 162.3, 162.9, 162.8 (d, J = 241.75 Hz); IR (KBr) 
3447, 1662, 1559, 1506 cm−1; MS (EI) m/z 446 (M+); HRMS Calcd for C26H23FN2O4 










7-Hydroxy-2-(4-methoxyphenylimino)-2H-chromene-3-carboxylic Acid [3-(4-Fluoro- 
phenyl)propyl]amide (18e). Yield 68%; mp 207−209 °C; 1H NMR (500 MHz, DMSO-d6) δ 
1.94 (2H, quint, J = 7.5 Hz), 2.70 (2H, t, J = 7.5 Hz), 3.46 (2H, t, J = 7.5 Hz), 3.84 (3H, s), 
6.62 (1H, s), 6.71 (1H, d, J = 8.5 Hz), 6.93 (4H, t, J = 8.5 Hz), 7.13 (2H, t, J = 8.5 Hz), 7.24 
(1H, s), (1H, d, J = 8.5 Hz), 8.452 (1H, s), 10.54 (1H, s); 13C NMR (125 MHz, DMSO-d6) δ 
35.2, 36.2, 42.9, 59.7, 105.8, 115.5, 117.5, 118.5, 119.4 (d, J = 21.9 Hz), 121.4, 129.2, 132.8 
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(d, J = 3.8 Hz), 134.9 (d, J = 8.5 Hz), 135.8, 141.5, 142.0 (d, J = 2.4 Hz), 145.1, 152.8, 165.1 (d, 
J = 240.6 Hz), 166.2, 166.8; IR (KBr) 3447, 1653, 1559, 1506 cm−1; MS (EI) m/z 446 (M+); 












7-Hydroxy-2-(4-methoxyphenylimino)-2H-chromene-3-carboxylic Acid [3-(3,5-Difluoro 
phenyl)propyl]amide (18f). Yield 85%; mp 230−232 °C; 1H NMR (500 MHz, DMSO-d6) δ 
1.86 (2H, quint, J = 7.5 Hz), 2.68 (2H, t, J = 7.5 Hz), 3.29−3.56 (2H, m), 3.77 (3H, s), 6.52 
(1H, d, J = 2.0 Hz), 6.71 (1H, dd, J = 6.5, 2.0 Hz), 6.94−7.02 (5H, m), 7.30 (2H, d, J = 9.0 Hz), 
7.61 (1H, d, J = 8.5 Hz), 8.39 (1H, s), 10.18 (1H, t, J = 5.5 Hz), 10.65 (1H, br); 13C NMR (125 
MHz, DMSO-d6) δ; 30.6, 32.8, 38.6, 55.7, 101.8 (t, J = 25.5 Hz), 111.5, 111.9 (dd, J = 24.3, 
4.9 Hz), 113. 5, 114.5, 117.4, 125.3, 131.6, 137.5, 141.1, 146.7 (t, J = 9.8 Hz), 148.8, 155.1, 
162.8 (d, J = 244.3 Hz), 156.3 (d, J = 237.0 Hz), 163.0, 169.3; IR (KBr) 3458, 1652, 1558, 
1506 cm−1; MS (EI) m/z 464 (M+); HRMS Calcd for C26H22F2N2O4 464.1548, 










7-Hydroxy-2-(4-methoxyphenylimino)-2H-chromene-3-carboxylic  Acid  (3-p-Tolyl- 
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propyl)amide (18g). Yield 82%; mp 220−222 °C; 1H NMR (500 MHz, DMSO-d6) δ 1.81 
(2H, quint, J = 7.3 Hz), 2.28 (3H, s), 2.49 (2H, t, J = 7.3 Hz), 3.25−3.39 (2H, m), 3.76 (3H, s), 
6.52 (1H, s), 6.73 (1H, dd, J = 2.0, 8.5 Hz), 6.49 (2H, d, J = 8.5 Hz), 7.06 (4H, q, J = 8.5 Hz), 
7.30 (2H, d, J = 8.5 Hz), 7.59 (1H, d, J = 8.5 Hz), 8.38 (1H, s), 10.20 (1H, t, J = 5.5 Hz); 13C 
NMR (125 MHz, DMSO-d6) δ 58.9, 68.2, 69.7, 75.8, 92.7, 138.8, 150.5, 151.5, 162.2, 165.7, 
166.4, 168.6, 172.2, 175.7, 178.1, 185.9, 192.1, 192.1, 193.8, 199.2; IR (KBr) 3227 1662, 











7-Hydroxy-2-(4-methoxyphenylimino)-2H-chromene-3-carboxylic Acid [3-(4-Methoxy 
phenyl)propyl]amide (18h). Yield 87%;  mp 198−200 °C; 1H NMR (500 MHz, DMSO-d6) 
δ 1.92 (2H, quint, J = 7.5 Hz), 2.67 (2H, t, J = 7.5 Hz), 3.45 (2H, q, J = 7.5 Hz), 3.75 (3H, s), 
3.82 (3H, s), 6.64 (1H, s), 6.73 (1H, d, J = 8.3 Hz), 6.78 (2H, d, J = 8.5 Hz), 6.90 (2H, d, J = 
9.0 Hz), 7.08 (2H, d, J = 8.5 Hz), 7.24−7.27 (3H, m), 7.32 (1H, d, J = 8.3 Hz), 8.43 (1H, s), 
10.65 (1H, br); 13C NMR (125 MHz, DMSO-d6) δ; 31.3, 32.2, 38.9, 55.4, 55.7, 101.8, 
111.5, 113.5, 114.2, 114.5, 117.4, 125.2, 129.7, 131.6, 133.7, 137.5, 141.1, 148.8, 155.1, 
156.8, 157.9, 162.2, 162.8; IR (KBr) 3441, 1652, 1558, 1506 cm−1; MS (EI) m/z 458 (M+); 













7-Hydroxy-2-(4-methoxyphenylimino)-2H-chromene-3-carboxylic Acid [4-(4-Methoxy- 
methoxyphenyl)butyl]amide (18i). Yield 83%; mp 179−181 °C; 1H NMR (500 MHz, 
CDCl3) δ 1.62−1.75 (4H, m), 2.60 (2H, t, J = 7.5 Hz), 3.46−3.49 (5H, m), 3.83 (3H, s), 5.14 
(2H, s), 6.63 (1H, s), 6.72 (1H, d, J = 8.5 Hz), 6.89−6.93 (4H, m), 7.06 (2H, d, J = 8.5 Hz), 
7.22 (2H, d, J = 8.5 Hz), 7.32 (1H, d, J = 8.5 Hz), 8.42 (1H, s), 10.59 (1H, t, J = 5.0 Hz); 13C 
NMR (125 MHz, CDCl3) δ 28.9, 29.2, 34.7, 35.0, 39.9, 55.5, 56.0, 78.5, 94.7, 102.5, 112.0, 
114.1, 116.3, 124.8, 129.4, 130.8, 135.7, 137.2, 141.2, 155.2, 155.4, 156.8, 162.0, 163.6, 
185.7; IR (KBr) 3442, 1652, 1558, 1506 cm−1; MS (EI) m/z 502 (M+); HRMS Calcd for 











2-(4-Methoxyphenylimino)-2H-chromene-3-carboxylic  Acid  [3-(4-Methoxymethoxy- 
phenyl)propyl]amide (18j). Yield 94%; mp 110−112 °C; 1H NMR (500 MHz, CDCl3) δ 1.94 
(2H, quint, J = 7.5 Hz), 2.70 (2H, t, J = 7.5 Hz), 3.46−3.50 (5H, m), 3.85 (3H, s), 5.14 (2H, 
s), 6.94 (4H, d, J = 8.5 Hz), 7.12 (3H, d, J = 8.5 Hz), 7.20 (1H, t, J = 8.5, Hz), 7.30 (2H, t, J = 
8.5 Hz), 7.44 (1H, t, J = 8.5 Hz), 7.51 (1H, dd, J = 2.0, 8.5 Hz), 8.52 (1H, s), 10.52 (1H, t, J = 
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5.5 Hz); 13C NMR (125 MHz, CDCl3) δ 32.8, 32.2, 28.8, 55.1, 55.5, 94.2, 113.7, 114.4, 
114.9, 116.0, 118.8, 121.2, 124.0, 124.6, 128.9, 129.1, 132.0, 134.5, 134.0, 147.9, 153.0, 
155.2, 156.6, 161.8; IR (KBr) 3447, 1653, 1558, 1506 cm−1; MS (EI) m/z 472 (M+); HRMS 











8-Hydroxy-2-(4-methoxyphenylimino)-2H-chromene-3-carboxylic Acid [3-(4-Methoxy- 
methoxyphenyl)propyl]amide (18k). Yield 89%; mp 192−194 °C; 1H NMR (500 MHz, 
CDCl3) δ 1.94 (2H, quint, J = 7.5 Hz), 2.68 (2H, t, J = 7.5 Hz), 3.45−3.84 (5H, m), 3.85 (3H, 
s), 5.15 (2H, s), 6.93−6.97 (5H, m), 7.06−7.13 (5H, m), 7.20−7.23 (2H, m), 8.53 (1H, s), 10.33 
(1H, br); 13C NMR (125 MHz, CDCl3) δ 20.7, 31.0, 32.4, 39.3, 55.4, 55.9, 94.5, 114.2, 116.3, 
119.2, 119.4, 120.6, 121.0, 124.4, 129.3, 134.7, 136.9, 138.8, 141.0, 143.0, 147.6, 155.4, 
156.9, 162.4; IR (KBr) 6424, 1662, 1558, 1506 cm−1; MS (EI) m/z 488 (M+); HRMS Calcd 
for C28H28N2O6 488.1947, Found 488.1952. 
 
General Procedure for the Synthesis of Coumarin (19a−l). 
10% HCl (5 drops) was added to a stirred solution of phenyliminochromene (18a−k, 1 
mmol) in THF (5 mL), and the resulting mixture was kept at 40 °C for 12 h. After 
cooling, H2O was added to the reaction mixture, and the aqueous mixture was 
extracted with EtOAc (5 mL ×3). The organic extracts were collected, dried over 
Na2SO4, and evaporated. The residue was chromatographed on silica gel (15 g, 
CH2Cl2/MeOH = 100:1) to give the pure coumarin (19a−l) as solid. The compounds 
for the measurement of mp, HPLC analysis, and biological tests were used after 
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7-Hydroxy-2-oxo-2H-chromene-3-carboxylic Acid [3-(3-Hydroxyphenyl)propyl]amide 
(19a). Yield 71%; mp 243−245 °C (MeOH); 1H NMR (500 MHz, DMSO-d6) δ 1.91 (2H, 
quint, J = 7.5 Hz), 2.64 (2H, t, J = 7.5 Hz), 3.44 (2H, q, J = 7.5 Hz), 6.65−6.66 (1H, m), 
6.71−6.74 (2H, m), 6.85 (1H, d, J = 2.5 Hz), 6.97 (1H, dd, J = 6.0, 2.5), 7.09 (1H, t, J = 8.0 
Hz), 7.79 (1H, d, J = 8.5 Hz), 8.74 (1H, br), 8.80 (1H, s); 13C NMR (125 MHz, DMSO-d6) δ 
31.1, 33.0, 102.3, 111.6, 113.3, 114.3, 114.9, 115.7, 119.4, 129.8, 132.5, 143.4, 148.4, 156.8, 
157.8, 161.6, 164.2; IR (KBr) 3340, 1700, 1545 cm−1; MS (EI) m/z 339 (M+); HRMS Calcd 









7-Hydroxy-2-oxo-2H-chromene-3-carboxylic Acid [3-(2-Hydroxyphenyl)propyl]amide 
(19b). Yield 64%; mp 220−222 °C (MeOH); 1H NMR (500 MHz, DMSO-d6) δ 1.92 (2H, 
quint, J = 7.5 Hz), 2.72 (2H, t, J = 7.5 Hz), 3.44 (2H, q, J = 7.5 Hz), 6.83−6.85 (2H, m), 
6.96−7.03 (2H, m), 7.14 (1H, d, J = 7.5 Hz), 8.80 (1H, s), 8.81 (1H, br); 13C NMR (125 MHz, 
DMSO-d6) δ 27.5, 29.8, 39.2, 102.3, 111.7, 114.3, 114.8, 115.4, 119.4, 127.4, 128.1, 130.3, 
132.4, 148.4, 155.6, 156.8, 161.6, 162.0, 164.1; IR (KBr) 3420, 1700, 1540, 1227 cm−1; MS 






O OHO OH  
 
7-Hydroxy-2-oxo-2H-chromene-3-carboxylic Acid [3-(4-Hydroxyphenyl)propyl]amide 
(19c). Yield 95%; mp 220−222 °C (MeOH); 1H NMR (500 MHz, acetone-d6) δ 1.84 (2H, 
quint, J = 7.5 Hz), 2.58 (2H, t, J = 7.5 Hz), 3.38 (2H, q, J = 7.5 Hz), 6.72 (2H, d, J = 8.5 Hz), 
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6.82 (1H, d, J = 2.0 Hz), 6.94 (1H, dd, J = 6.5, 2.0 Hz), 6.04 (2H, d, J = 8.5 Hz), 7.76 (1H, d, J 
= 8.5 Hz), 8.69 (1H, br), 8.77 (1H, s); 13C NMR (125 MHz, DMSO-d6) δ 31.5, 32.2, 39.1, 
102.3, 111.6, 114.3, 114.9, 115.6, 129.6, 132.0, 132.5, 148.4, 155.9, 156.8, 161.6, 162.1, 
164.1; IR (KBr) 3442, 1734, cm−1; MS (EI) m/z 339 (M+); HRMS Calcd for C19H17NO5 









7-Hydroxy-2-oxo-2H-chromene-3-carboxylic Acid [3-(3-Fluorophenyl)propyl]amide (19d). 
Yield 90%; mp 209−210 °C (MeOH); 1H NMR (500 MHz, DMSO-d6) δ 1.83 (2H, quint, J 
=7.5 Hz), 2.64 (2H, t, J = 7.5 Hz), 3.21−3.35 (2H, m), 6.79 (1H, s), 6.86 (1H, dd, J = 2.0, 8.5 
Hz), 6.98 (1H, t, J = 8.5 Hz), 7.05 (2H, d, J = 8.5 Hz), 7.30 (1H, q, J = 8.5 Hz), 7.80 (2H, d, J 
= 8.5 Hz), 8.66 (1H, t, J = 5.8 Hz), 8.75 (1H, s); 19F NMR (376 MHz, DMSO-d6) δ −113.67; 
13C NMR (125 MHz, DMSO-d6) δ 30.9, 32.7, 39.0, 102.3, 111.7, 113.1(d, J = 20.63 Hz), 
114.4, 114.9, 115.5 (d, J = 20.6 Hz), 125.0 (d, J = 2.5 Hz), 125.3, 130.7 (d, J = 8.6 Hz), 125.3, 
130.7 (d, J = 10.7 Hz), 132.5, 145.1 (d, J = 6.0 Hz), 148.4, 156.8, 161.6, 163.1 (d, J = 246.8 
Hz), 163.8; IR (KBr) 3562, 1705, 1550, 1226 cm−1; MS (EI) m/z 341 (M+); HRMS Calcd for 





O OHO F  
 
7-Hydroxy-2-oxo-2H-chromene-3-carboxylic Acid [3-(4-Fluorophenyl)propyl]amide (19e). 
Yield 96%; mp 207−209 °C (EtOH); 1H NMR (500 MHz, DMSO-d6) δ 1.95 (2H, quint, J = 
7.5 Hz), 2.70 (2H, t, J = 7.5 Hz), 3.49 (2H, q, J = 7.5 Hz), 6.88−6.91 (2H, m), 6.94−6.98 (2H, 
m), 7.14−7.18 (2H, m), 7.20−7.23 (1H, m), 7.57 (1H, d, J = 8.5 Hz), 8.83 (1H, s), 8.87 (1H, 
br); 19F NMR (376 MHz, DMSO-d6) δ −117.54; 13C NMR (125 MHz, DMSO-d6) δ; 31.3, 
32.1, 39.0, 102.3, 111.6, 114.3, 114.8, 115.4 (d, J = 20.6 Hz), 128.8 (d, J = 3.6 Hz), 130.5 (d, J 
= 8.6 Hz), 132.4, 138.1, 148.4, 156.7, 156.7, 161.1 (d, J = 239.9 Hz), 164.6, IR (KBr) 3572, 
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1717, 1558, 1267 cm−1; MS (EI) m/z 341 (M+); HRMS Calcd for C19H16FNO4 341.1063, 










7-Hydroxy-2-oxo-2H-chromene-3-carboxylic Acid [3-(3,5-Difluorophenyl)propyl]amide 
(19f). Yield 92%; mp 213-214 °C (MeOH); 1H NMR (500 MHz, DMSO-d6) δ 1.85 (2H, quint, 
J = 7.5 Hz), 2.67 (2H, t, J = 7.5 Hz), 3.27−3.41 (2H, m), 6.81 (1H, s), 6.88 (2H, d, J = 8.5 Hz), 
6.99−7.02 (3H, m), 7.82 (1H, d, J = 8.5 Hz), 8.67 (1H, t, J = 5.5 Hz), 8.78 (1H, s); 19F NMR 
(376 MHz, DMSO-d6) δ −110.54; 13C NMR (100 MHz, DMSO-d6) δ 30.5, 32.6, 38.9, 
101.7 (t, J = 28.3 Hz), 102.3, 111.6, 111.9 (dd, J = 4.9, 19.4 Hz), 114.2, 114.8, 132.4, 146.8 (t, 
J = 9.1 Hz), 148.4, 156.7, 161.5, 162.8 (d, J = 244.3 Hz), 162.1, 162.9 (d, J = 244.3 Hz), 
164.1; IR (KBr) 3227, 1718, 1549, 1226 cm−1; MS (EI) m/z 359 (M+); HRMS Calcd for 





O OHO  
 
7-Hydroxy-2-oxo-2H-chromene-3-carboxylic Acid (3-p-Tolylpropyl)amide (19g).  Yield 
90%; mp 220−222 °C (MeOH); 1H NMR (500 MHz, DMSO-d6) δ 1.79 (2H, quint, J = 7.5 
Hz), 2.23 (3H, s), 2.56 (2H, t, J = 7.5 Hz), 3.25−7.37 (2H, m), 6.78 (1H, s), 6.80 (1H, dd, J = 
2.0, 8.5 Hz), 7.05 (4H, q, J = 8.5 Hz), 7.79 (1H, d, J = 8.5 Hz), 8.64 (1H, t, J = 5.8 Hz), 8.74 (1H, 
s); 13C NMR (125 MHz, DMSO-d6) δ 21.1, 31.3, 32.6, 39.1, 102.3, 111.7, 114.4, 114.8, 
128.7, 129.4, 132.5, 135.1, 138.9, 148.4, 156.8, 161.6, 162.0, 164.1; IR (KBr) 3214, 1715, 
1549 cm−1; MS (EI) m/z 337 (M+); HRMS Calcd for C20H19NO4 337.1314, Found 337.1311; 







O OHO OMe  
 
7-Hydroxy-2-oxo-2H-chromene-3-carboxylic Acid [3-(4-Methoxyphenyl)propyl]amide 
(19h).  Yield 95%; mp 205−207 °C (MeOH); 1H NMR (500 MHz, acetone-d6) δ 1.95 (2H, 
quint, J = 7.5 Hz), 2.69 (2H, t, J = 7.5 Hz), 3.47 (2H, q, J = 7.5 Hz), 3.79 (3H, s), 6.87−6.89 
(3H, m), 7.02 (1H, dd, J = 6.0, 2.5 Hz), 7.21 (2H, d, J = 6.5 Hz), 7.84 (1H, d, J = 8.5 Hz), 8.76 
(1H, br), 8.84 (1H, s); 13C NMR (125 MHz, DMSO-d6) δ 31.4, 32.1, 39.1, 55.4, 102.3, 111.6, 
114.2, 114.3, 114.8, 129.7, 132.4, 133.8, 148.4, 156.7, 157.9, 161.6, 162.0, 164.1; IR (KBr) 
3318, 1706, 1540 cm−1; MS (EI) m/z 353 (M+); HRMS Calcd for C20H19NO5 353.1263, 









7-Hydroxy-2-oxo-2H-chromene-3-carboxylic Acid [4-(4-Hydroxyphenyl)butyl]amide (19i).  
Yield 66%; mp 225−226 °C (MeOH); 1H NMR (500 MHz, DMSO-d6) δ 1.59−1.63 (4H, m), 
2.55 (2H, t, J = 7.5 Hz), 3.45 (2H, q, J = 7.5 Hz), 6.75 (2H, d, J = 8.5 Hz), 6.82 (1H, d, J = 2.0 
Hz), 6.95 (1H, dd, J = 6.5, 2.0 Hz), 7.01 (2H, d, J = 8.5 Hz), 7.76 (1H, d, J = 8.5 Hz), 8.10 (1H, 
br), 8.76 (1H, s); 13C NMR (125 MHz, DMSO-d6) δ 29.2, 29.2, 34.4, 39.3, 102.3, 111.6, 
114.2, 114.8, 115.5, 129.6, 132.4, 132.6, 148.4, 155.8, 156.7, 161.6, 161.9; IR (KBr) 3312, 
1707, 1550 1227 cm−1; MS (EI) m/z 353 (M+); HRMS Calcd for C20H19NO5 353.1263, 










2-Oxo-2H-chromene-3-carboxylic Acid [3-(4-Hydroxyphenyl)-propyl]amide (19j). Yield 
67%; mp 194−196 °C (MeOH); 1H NMR (500 MHz, DMSO-d6) δ 1.92 (2H, quint, J = 7.5 
Hz), 2.65 (2H, t, J = 7.5 Hz), 3.27−3.41 (2H, m), 6.76 (2H, d, J = 8.5 Hz), 7.06 (2H, d, J = 
8.5 Hz), 7.37−7.42 (2H, m), 7.67 (2H, m), 8.92 (1H, s); 13C NMR (125 MHz, DMSO-d6) δ 
31.4, 32.1, 39.8, 115.6, 116.6, 119.0, 119.7, 125.6, 129.6, 130.7, 131.9, 134.5, 147.7, 154.3, 
155.9, 160.9, 161.6; IR (KBr) 3345, 1717, 1608, 1569 cm−1; MS (EI) m/z 323 (M+); HRMS 












8-Hydroxy-2-oxo-2H-chromene-3-carboxylic Acid [3-(4-Hydroxyphenyl)propyl]amide 
(19k).  Yield 86%; mp 225−227 °C (MeOH); 1H NMR (500 MHz, acetone-d6) δ 1.93 (2H, 
quint, J = 7.5 Hz), 2.67 (2H, t, J = 7.5 Hz), 3.45 (2H, q, J = 7.5 Hz), 6.80 (2H, d, J = 8.5 Hz), 
7.12 (2H, d, J = 8.5 Hz), 7.29−7.41 (2H, m), 7.45 (1H, t, J = 5.0 Hz), 8.14 (1H, s), 8.82 (1H, 
br), 8.89 (1H, s); 13C NMR (125 MHz, DMSO-d6) δ 31.4, 32.1, 39.2, 115.6, 119.5, 119.9, 
120.5, 125.6, 129.6, 131.9, 143.0, 144.9, 148.1, 155.8, 160.8, 161.7; IR (KBr) 3390, 1718, 
1610 cm−1; MS (EI) m/z 339 (M+); HRMS Calcd for C19H17NO5 339.1107, Found 339.1108; 









7-Hydroxy-2-oxo-2H-chromene-3-carboxylic Acid [2-(4-Hydroxyphenyl)ethyl]amide (19l). 
Yield 65%; mp 271−273 °C (MeOH); 1H NMR (500 MHz, DMSO-d6) δ 2.81 (2H, t, J = 7.5 
Hz), 3.61 (2H, q, J = 7.5 Hz), 6.78 (2H, dd, J = 4.5, 2.0 Hz), 7.11 (2H, dd, J 13C NMR (125 
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MHz, DMSO-d6) δ 34.7, 41.4, 102.3, 111.6, 114.0, 114.9, 115.7, 129.7, 130.0, 132.5, 148.5, 
156.2, 161.5, 161.9, 164.2; IR (KBr) 3313, 1709, 1539 cm−1; MS (EI) m/z 325 (M+); HRMS 
Calcd for C19H17NO5 325.3154, Found 325.0947; Purity 96% (HPLC).  
 
Improved Synthesis of 19e.  
LiAlH4 (136 mg, 3.6 mmol) was added to a stirred solution of 
p-fluorobenzenepropanamide (200 mg, 1.2 mmol) in THF (10 mL) , and the 
resulting suspension was refluxed for 18 h. After cooling, the reaction mixture was 
diluted with AcOEt (10 mL) and then quenched with 10% NaOH aq in ice. The 
insoluble materials were filtered off using Celite, and the filtrate was dried over 
Na2SO4 and collected in vacuo to yield corresponding amine, which was used for the 
next reaction without further purification. 7-hydroxycoumarin-3-carboxylic acid (190 
mg, 0.9 mmol) and EDC (265 mg, 1.4 mmol) were added to a stirred solution of the 
amine obtained above in THF (6 mL) at 25oC, and the resulting mixture was stirred 
at 25oC for 1 h. To the reaction mixture was added N-methylmorpholine (0.2 mL, 1.8 
mmol), and the reaction mixture was stirred at 25oC for 18 h. The reaction mixture 
was diluted with AcOEt (10 mL) and 10% HCl aq., and the organic phase was 
collected; the aqueous mixture was extracted with AcOEt (5 mL × 3). The organic 
phase and extracts were collected, dried over Na2SO4, and concentrated in vacuo. The 
residue was chromatographed on SiO2 (20 g, CH2Cl2/MeOH = 100:1) to give pure 
19e (314 mg, 78%) as a yellow solid.  
 
Enzyme Purification. 
Homogenous recombinant AKR1B10, AKR1B1,41 AKR1A1, AKR1C isoforms 
(1C1−1C4),42,43 CBR1, and mutant enzymes of AKR1B10 (K125L, W220Y, V301L, 
and Q303S)44,45 were made and purified to homogeneity as previously said. All 
enzymes were kept at −20 °C in 10 mM potassium phosphate buffer, pH 7.0, containing 
20% glycerol, 1 mM EDTA, and 5 mM 2-mercaptoethanol.  
Enzyme Activity Assay.  
The potency of the compounds was assayed by measuring their ability to inhibit the 
reductase or dehydrogenase activities of the enzymes, which were determined at 25 °C 
by measuring the rate of change in NADPH absorbance at 340 nm. The reaction mixture 
(total volume of 2.0 mL) consisted of 0.1 M potassium phosphate, pH 7.4, coenzyme 
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(0.1 mM NADPH or 0.25 mM NADP+), substrate, enzyme, and inhibitor. The 
inhibitors were hold in methanol and added to the reaction mixture, not to exceed 2% 
methanol concentration. The reaction was acted by the addition of the enzyme. The 
enzyme concentrations of AKR1B10 and AKR1B1 were 3−6 μg/mL. The IC50 values 
for inhibitors were tested in the NADPH-linked reductase activities toward 0.2 mM 
pyridine-3-aldehyde (for AKR1B10 and AKR1B1), 2 mM pyridine-3-aldehyde (for 
AKR1A1), and 50 μM isatin (for CBR1). In the IC50 determination of AKR1C1−1C4, 
their NADP+-linked dehydrogenase activities were determined using 
(S)-(+)-1,2,3,4-tetrahydro- 1-naphthol (S-tetralol) as the substrate. Kinetic studies of 
AKR1B10 and its mutant enzymes in the presence of inhibitors were performed in 
NADP+-linked geraniol oxidation over a range of five substrate concentrations [(0.5−5) 
× Km] at a saturating concentration (0.25 mM) of the coenzyme. The inhibition patterns 
were investigated from the Lineweaver−Burk plots (double reciprocal plots of the initial 
velocities versus concentrations of substrate), and Ki (inhibition constant) for the 
competitive inhibitor was tested from replots of the slopes of the Lineweaver−Burk 




Molecular Modeling.  
The modeling of binding mode of 19c with AKR1B10 was carried out using the 
Schrödinger suite 2013-2 (Schrödinger, LLC, New York, NY, 2013). The 3D structure 
of 19c was first generated using the LigPrep 2.7 program. The conformational search of 
19c was then carried out using the ConfGen 2.5 program, and the resulting conformers 
were included in the following docking calculations. The X-ray structure of the 
AKR1B10 in complex with caffeic acid phenethyl ester (CAPE) (PDB ID 4GQ0) was 
used as a receptor for docking. Because CAPE forms a similar chemical structure to 19c, 
it would be more sufficient to use the receptor structure derived from the 
CAPE−AKR1B10 complex. The X-ray structure was minimized using force-field OPLS 
2005 through the Protein Preparation Wizard in Maestro 9.5. We removed H2O 
molecules in front of docking calculations. The docking calculation of 19c against 
AKR1B10 was carried out using the Glide 6.0 SP mode. Box center for the “Receptor 
Grid Generation” protocol was set to a centroid of CAPE linking AKR1B10. The van 
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der Waal radius scaling of 1.0 was used for both protein and ligand, and the maximum 
number of poses per conformer was set to 2. The generated poses were ranked 
according to docking score, and we finally chosed a docked complex with the lowest 
docking score as the interaction model. In order to test the docking procedure, we 
considered it for the CAPE−AKR1B10 complex. The positional and conformational 
rootmean- square deviations between X-ray and docked poses were 0.34 and 0.17 Å, 
respectively. This result told that the procedure is adequate for producing a reliable 
binding model between CAPE and AKR1B10.  
 
Cell Culture. 
Lung cancer A549 cells were obtained from American Type Culture Collection 
(Manassas, VA, USA) and trained in Dulbecco’s modified Eagle medium (DMEM) 
supplemented with 10% fetal bovine serum, penicillin (100 U/mL), and streptomycin 
(100 μg/mL) at 37 °C in a humidified incubator environment 5% CO2. The A549/1B10 
cells and CDDP-R-A549 cells were established as reported recently. For establishment 
of the subpopulation resistant to CDDP, the A549 cells47,48 were continuously grown in 
the growth medium supplemented with CDDR whose concentration was increased in a 
stepwise manner (0.05−5 μM).  
 
Metastatic and Invasive Potential. 
Migrating potential of the cells was assayed by wound-healing and Boyden chamber 
assays as described previously. Shortly, the cells were seeded into a 6-well culture plate 
at a density of 3 × 105 cells/well. After reaching a 90% confluence of the cells, the cell 
monolayer was scratched with a 10-μL pipet tip, cleaned twice with the growth medium, 
and then incubated for 24-h in serum-free DMEM supplemented with AKR1B10 
inhibitors or the vehicle DMSO, aiming to allow the cells to migrate from the wound 
surface to the cell-free area. The migrating potential was evaluated by microscopically 
measuring the width of the cell-free area. In the situation of the Boyden chamber assay, 
the cells were seeded on a polycarbonate membrane (8-μm pore) at a density of 1 × 104 
cells/well and cultured for 36 h. After medium in the above layer of the membrane was 
replaced with fresh growth medium, the cells were incubated for 48 h in serum-free 
DMEM supplemented with AKR1B10 inhibitors or the vehicle DMSO. The cells that 
migrated to the underside of the membrane were fixed with methanol and stained with 
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Giemsa solution, and their number was counted microscopically. Invasive activity of 
cells was likely analyzed using the polycarbonate membrane coated with type-I collagen 
(Nitta Gelatin, Osaka, Japan).  
 
Statistical Analysis. 
Data are expressed as the means ± SD of at least three independent experiments, 
unless otherwise noted. Statistical evaluation of the data was carried out by using the 























To a stirred solution of the acetic acid (0.286 mL, 5 mmol) in concentrated H2SO4 (6 
mL) was added thiosemicarbazide 20a (547 mg, 6 mmol) at room temperature, and the 
mixture was stirred for 6 h at 100 oC. After cooling to 0 oC, the reaction mixture was 
nuetralized by NH3 (aq). The aqueous mixture was filtered and the crystal was 
recrystallized from EtOH to give 20b (314 mg, 55%) as a colorless solid.  








2-[[(5-methyl-1,3,4-thiadiazol-2-yl)amino]methylene]-propanedioic acid 1,3-dimethyl ester 
(20c). 
To a stirred solution of 20b (200 mg, 1.737 mmol) in toluene (10 mL) was added the 
ester e (302 mg, 1.737 mmol) at room temperature, and the reaction mixture was 
refluxed for 12 h. The reaction mixture was evaporated, and the residue was 
chromatographed on silica gel (15g, hexane/acetone = 5:1) to give 20c (302 mg, 68 %) 












2-Methyl-5-oxo-5H-thiadiazolo[3,2-a]pyrimidine-6-carboxylic acid methyl ester (20d). 
To a stirred solution of 20c (141 mg, 0.5 mmol) in toluene (10 mL) was added BF3∙
Et2O (0.138 mL, 1 mmol) at room temperature, and the reaction mixture was refluxed 
for 12 h. After cooling, the reaction was quenched by H2O. The aqueous mixture was 
extracted with EtOAc (5 mL × 3). The organic extracts were combined, dried over 
Na2SO4, and evaporated. The residue was chromatographed on silica gel (15g, 
hexane/acetone = 1:1) to give 20d (79 mg, 59%) as a yellow solid. 










2-Methyl-5-oxo-5H-thiadiazolo[3,2-a]pyrimidine-6-carboxylic acid (20). 
To a stirred solution of 20d (50 mg, 0.2 mmol) in pyridine (5 mL) was added LiI (45 mg, 
0.3 mmol) at room temperature, and the reaction mixture was refluxed for 3 days. After 
cooling, to the reaction mixture was added 10% HCl (1 drop) and extracted with EtOAc 
(3 mL × 3). The organic extracts were combined, dried over Na2SO4, and evaporated. 
The residue was chromatographed on silica gel (15 g, CH2Cl2/MeOH = 10:1) and 
washed by acetone to give 20 (10 mg, 21%) as a yellow solid. 
1H NMR (500 MHz, CD3OD) δ 2.81 (3H, s), 8.88 (1H, s). 
 
Virtual screening and molecular docking 
In silico large-scale screening of ligands was performed using an original program
“NAGARA”. NAGARA is a plugin for PyMOL (DeLano Scientific, San Carlos, CA) 
and integrates three main GUIs: 1) Docking simulation (DS), a GUI for DSs and 
large-scale screening via AutoDock Vina; 2) Molecular dynamics (MD), a GUI for 
obtaining the stable structure of protein–ligand complexes and the binding free energy 
in MD simulations via the Amber package; and 3) Quantum chemistry (QC), a PAICS 
GUI for optimizing the MC molecular structure by QC calculations. The structure of 
Atg4B was picked up from the crystal structure of human Atg4B-LC3(1–124) complex 
(PDB ID: 2Z0E). The ligand database was obtained from Asinex subset (~360,000 
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compounds) of LigandBox (Asinex Ltd, Moscow, Russia) . The docking area covered 
the binding area of Atg4B with LC3. In the parameter setting of AutoDock Vina, the 
exhaustiveness value and maximum number of generated binding modes were set to 8 
and 9, respectively, the maximum difference between energies of the best and the worse 
binding modes was as large as 4 kcal/mol, and other optional settings were set to their 
default values. The inhibitor-docked models were generated using PyMOL. The 
compounds 20˗37 were obtained from Asinex Ltd. 
 
Cell culture 
Lung cancer A549 cells were obtained from American Type Culture Collection 
(Manassas, VA), and grown in Dulbecco’s modified Eagle medium (DMEM) 
supplemented with 10% fetal bovine serum, penicillin (100 U/mL) and streptomycin 
(100 μg/mL) at 37 °C in a humidified incubator containing 5% CO2. The A549/CDDP 
cells were established as reported previously. For establishment of the CDDP-resistant 
cells, the A549 cells were continuously treated in the growth medium supplemented 
with CDDP, whose concentration was increased in a stepwise manner (0.05–5 μM). To 
evaluate sensitivity of A549 cells and A549/CDDP cells to tamoxifen or CDDP, the cells 
were seeded into a 96-well multiplate at a density of 2 × 104 cells/well, and then treated 
for 24 h with PI3K inhibitors (3MA and Wo) or Atg4B inhibitors in the presence or 
absence of tamoxifen or CDDP. DMSO was used as a vehicle of the agents. Drug 
sensitivity of the cells was estimated by monitoring the cell viability, which was 
evaluated by tetrazolium dye-based cytotoxicity assay using 
2-(4-iodophenyl)-3-(4-nitrophenyl)-5- (2,4-disulfophenyl)-2H-tetrazolium. 
 
Western blot analysis 
Cells were washed twice with Dulbecco's phosphate buffered saline (DPBS), suspended 
in Urea buffer (10mM Tris-HCl pH 8.0, containing 50mM NaH2PO4 and 8M urea), and 
homogenized by sonication. The cell extract was prepared by centrifugation (12,000×g 
for 15 min) of the homogenate and protein concentration was determined with the 
bicinchoninic acid protein assay reagent (Nacalai Tesque, Kyoto, Japan). Proteins in the 
extract (20 μg) were separated by SDS-PAGE, and then transferred to a polyvinylidene 
difluoride membrane by electroblotting. The membrane was blocked with 50mM 
Tris-buffered saline with 0.05% Tween-20 (TBS-T) containing 5% skim milk, and 
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incubated overnight at 4 °C with the TBS-T supplemented with primary antibodies 
against LC3 (#PM036, MBL, Nagoya, Japan), Bax (#CSBPA000976, Wuhan Huamei 
Biotech Co., Hubei, China), Bcl-2 (#D038-3, MBL) or β-actin (#4970, Cell Signaling 
Technology, Beverly, MA) as the loading control. After washing with the TBS-T, the 
membrane was incubated with horseradish peroxidase-conjugated secondary antibody 
against rabbit immunoglobulin. The immunopositive bands were visualized using an 
enhanced chemiluminescence reagent (GE Healthcare, Buckinghamshire, UK). The 
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